Document:

EX-10.14

					
		 	 Confidential Materials omitted and filed separately with the

Securities and Exchange Commission. Double asterisks denote omissions.
	 	Exhibit 10.14

 LICENSE AGREEMENT 

between 
 GENABLE
TECHNOLOGIES LIMITED 
 and 

SPARK THERAPEUTICS, LLC 

 This License Agreement (the “Agreement”) is entered into this 18th day of March, 2014 (the “Effective Date”), by and between Genable Technologies Limited, organized and existing under the laws of Ireland, and having a principal place of
business at Media House, South County Business Park, Leopardstown, Dublin 18, Ireland (“Genable”) and Spark Therapeutics, LLC, organized and existing under the laws of Delaware, USA, and having a principal place of business at 3501
Civic Center Boulevard, Philadelphia, PA 19104, USA (“Spark”). 
 Genable and Spark may collectively be referred to as the
“Parties” and each a “Party”. 
 Spark and Genable agree as follows: 

 

	1.	BACKGROUND 

  

	 	1.1	Pursuant to agreements dated October 14, 2013, Spark has acquired or licensed from The Children’s Hospital of Philadelphia (“CHOP”) certain patent rights and confidential and trade secret
information relating to the manufacture of adeno-associated virus vectors as therapeutic agents for various indications and conditions. 

  

	 	1.2	Genable desires to obtain from Spark an exclusive right and license under such patent rights and confidential and trade secret information for the development and commercialization of therapeutic agents for the
treatment of rhodopsin-linked, autosomal dominant retinitis pigmentosa (“RHO-adRP”). Spark is willing to grant such right and license to Genable. 

 

	 	1.3	Simultaneous with this Agreement, Spark and Genable have entered into the Development Agreement and the Manufacturing Agreement. 

  

	2.	DEFINITIONS 

  

	 	2.1	“Affiliate(s)” shall mean any corporation, firm, partnership or other entity, which controls, is controlled by, or is under common control with, a Party. For purposes of this Paragraph 2.1,
“control” shall mean direct or indirect ownership of fifty percent (50%) or more of the outstanding stock or other voting rights entitled to elect directors thereof or the ability to otherwise control the management of such
corporation, firm, partnership or other entity. Notwithstanding the foregoing, CHOP shall be deemed not to be an Affiliate of Spark. 

  

	 	2.2	“Commercially Reasonable Efforts” means the carrying out of applicable obligations under this Agreement in a commercially reasonable manner in good faith using all such efforts and resources consistent
with the practice of comparable biological development companies of a similar size and resources, both financial and otherwise, to those of Genable, that would be used by such companies were they developing a comparable biological product;

  

	 	2.3	“CHOP License Agreement” means the License Agreement dated as of October 14, 2013, by and between Spark (f/k/a AAVenue Therapeutics, LLC) and CHOP. 

 

	 	2.4	 “Clinical Trial” means an investigation in human subjects and/or patients intended to discover or verify the clinical,
pharmacological and/or other pharmacodynamic effects of a Licensed Product, and/or to identify any adverse reactions to a 

  
 2 

	 	
Licensed Product, and/or to study absorption, distribution, metabolism, and/or excretion of a Licensed Product with the objective of ascertaining its safety, activity and/or efficacy.

  

	 	2.5	“Confidential Know-How” means any and all rights, other than Patent Rights, in any scientific, pharmaceutical or technical information, know-how, discovery, invention, process, procedure, composition,
method, formula, protocol, technique, or data owned or controlled by Spark and maintained in confidence or as a trade secret by Spark which are not covered by the Patent Rights and which are used for practicing or manufacturing the Licensed Products
and/or relating to the Licensed Field. Confidential Know-How includes but is not limited to the information set out in Appendix A. 

  

	 	2.6	“Development Consultancy Agreement” means the development consultancy agreement of even date entered into by the Parties, subject to terms and conditions set out therein. 

 

	 	2.7	“EMA” means the European Medicines Agency or any successor agency thereof having the authority to regulate the sale of medicinal or pharmaceutical products in the European Union through marketing
approval, not including any governmental authority with responsibility solely for pricing or reimbursement approvals. 

  

	 	2.8	“FDA” means the United States Food and Drug Administration or any other successor agency whose approval is necessary to market the Licensed Product in the USA. 

 

	 	2.9	“First Commercial Sale” means the first sale during a full scale commercial launch by or on behalf of Genable or its sublicensees of Licensed Products in an arm’s length transaction to an
independent third party in any country in the Territory after all applicable required Regulatory Approvals in such country, in exchange for cash or some cash equivalent to which value can be assigned for the purpose of determining Net Sales.

  

	 	2.10	“GT038” means a gene therapeutic comprising an AAV vector containing DNA encoding an RNAi targeting rhodopsin in combination with an AAV vector containing DNA encoding a rhodopsin gene for the treatment
of RHO-adRP, which is in development by Genable as of the Effective Date, and as such gene therapeutic may be modified after the Effective Date. 

  

	 	2.11	“Improvements” means any and all improvements, developments, adaptions, enhancements, alterations or modifications to the Spark Intellectual Property, whether or not patentable, which are either made,
owned or licensed by or on behalf of Spark. 

  

	 	2.12	“Licensed Field” means adeno-associated virus (“AAV”) based therapeutic agents for the treatment of RHO-adRP. 

 

	 	2.13	 “Licensed Products” means any product incorporating GT038 in the Licensed Field sold by or on behalf of Licensee, its Affiliates,
licensees or its sublicensees, the manufacture, use or sale of which is covered by a claim of the Patent Rights or utilizes Confidential Know-How of Spark in the country of such manufacture, use or

  
 3 

	 	
sale but for the license granted herein. For the avoidance of doubt, all products supplied by Spark to Genable pursuant to the Manufacturing Agreement shall be deemed to utilize Confidential
Know-How of Spark. 

  

	 	2.14	“Licensed Territory” means worldwide. 

  

	 	2.15	“Manufacturing Agreement” means the manufacturing agreement of even date entered into by the Parties pursuant to which Spark is appointed the exclusive manufacturer of the Licensed Product for Genable,
subject to terms and conditions set out therein. 

  

	 	2.16	“Net Sales” means the total gross receipts invoiced by Genable, its Affiliates, licensees and sublicensees for sales, including transfers of Licensed Products to others for value or making Licensed
Products available to others for value, of Licensed Products by or on behalf of Genable, its Affiliates, licensees or sublicensees, less: 

  

	 	(a)	sales returns and allowances actually given to third parties, including, trade, quantity and cash discounts and other adjustments (retroactive or otherwise), including, but not limited to, those granted on account of
price adjustments, billing errors, rejected goods, damaged or defective goods, recalls, returns, rebates, stocking allowances, reimbursements or similar payments actually made to customers, wholesalers or distributors, provided however that any
discretionary rebates, discounts, adjustments or similar payments shall be commercially reasonable and consistent with standard industry practices; 

  

	 	(b)	insurance and freight charges and transportation costs actually paid to third parties for the shipment of Licensed Products; 

  

	 	(c)	customs or excise duties, sales tax, consumption tax and other taxes (except income taxes) or duties relating to sales of Licensed Products to third parties that are actually paid by Genable; and 

 

	 	(d)	invoiced amounts that are subsequently written off as uncollectible, provided that if any such amounts are collected after having been written off, such amounts shall thereupon be reincluded in Net Sales.

 No deductions shall be made for commissions paid to any third party or individual (whether they be with independent sales
agencies or regularly employed by Genable, its Affiliates, licensees or sublicensees, and on its payroll) or for the cost of collections. 

Notwithstanding the foregoing, “Net Sales” shall not include amounts (i) for any Licensed Product furnished to a third party
for use in Clinical Trials, for compassionate use or as promotional samples, in either case for which payment (other than the cost of the Licensed Product) is not intended to be received or (ii) from sales or other dispositions of Licensed
Products among Licensee and any of its Affiliates, licensees or sublicensees, unless the Affiliate, licensee or sublicensee, as the case may be, is an end-customer of such Licensed Product. 

  
 4 

	 	2.17	“Patent Rights” means all patent applications and/or patents, now existing, currently pending, or, if associated with Improvements, hereinafter filed, owned and/or controlled by Spark, with respect to
the manufacture, purification, process development and preparation of proviral plasmids and recombinant AAV, including the application and/or patents set forth on Appendix A, and any foreign counterparts thereof and all patents issuing therefrom, as
well as any continuations, continuations-in-part, divisions, reexaminations, reissues, substitutes, renewals or extensions thereof, and any foreign counterparts thereof. 

 

	 	2.18	“Regulatory Application” means any regulatory application or any other application for marketing approval for the Licensed Product, which Licensee will file in the Territory, including any supplements
or amendments thereto which Licensee may file. 

  

	 	2.19	“Regulatory Approval” means the final approval to market the Licensed Product in any country of the Territory, including pricing and reimbursement approval and any other approval which is required to
launch the Licensed Product in the normal course of business. 

  

	 	2.20	“Spark Intellectual Property” means the Patent Rights and Confidential Know-How and Improvements. 

  

	 	2.21	“Year” means each twelve-month period beginning on January 1 and ending on 31 December during the term of this Agreement. 

 

	 	2.22	“$” means United States Dollars. 

  

	3.	GRANT OF RIGHTS 

  

	 	3.1	Spark hereby grants and Genable accepts, subject to the terms and conditions of this Agreement, a worldwide, royalty-bearing exclusive license (even as to Spark) to the Spark Intellectual Property with the right to
sublicense, to research, develop, import, use, have used, make and have made, market, offer for sale, distribute, sell, and have sold, the Licensed Products within the Licensed Field in the Licensed Territory (the “License”).

  

	 	3.2	Pursuant to the Manufacturing Agreement, Genable shall appoint Spark as the exclusive manufacturer of the Licensed Product. Genable shall not exercise its license to manufacture Licensed Products other than to the
extent permitted by the Manufacturing Agreement. 

  

	 	3.3	Spark will provide a third party nominated by Genable and reasonably acceptable to Spark, pursuant to an appropriate material custody agreement, with sufficient cells from Spark’s Master Cell Bank (MCB) comprised
of [**] cells and any additional Working Cell Banks (WCB) that may be used by Spark for the manufacture of Licensed Product(s) in the future, in order that the third party may established a second MCB in order to comply with regulatory requirements.
Subject to the terms of the Manufacturing Agreement, Genable shall be entitled to have the third party transfer this second MCB to a third party contract manufacturer in order to transfer the manufacturing process(es) for the Licensed Product(s) to
a third party contract manufacturer reasonably acceptable to Spark in accordance with an appropriate material custody agreement between the third party contract manufacturer and Spark. 

  
 5 

	 	3.4	For the avoidance of doubt, Spark shall not license to, nor permit the use by, any third party of the Spark Intellectual Property for the sale or distribution of Licensed Products in the Licensed Field in the Licensed
Territory. 

  

	 	3.5	Spark acknowledges that Genable has considerable proprietary know-how and data related to GT038 and has filed patent applications and obtained patents world-wide in relation to GT038. Nothing in this Agreement shall
grant Spark any rights of any nature whatsoever to GT038, provided that, Genable hereby grants to Spark a license to such know-how, data and patent rights, on a non-exclusive, non-sub-licensable, non-royalty-bearing basis solely to the extent
necessary for Spark to perform its obligations under the Manufacturing Agreement and the Development Consultancy Agreement. 

  

	 	3.6	The Licensed Field may be expanded or modified by mutual written agreement between the Parties. 

  

	 	3.7	Spark will in good faith promptly disclose in writing to Genable any Improvements having application to Licensed Products in the Licensed Field. Any such Improvement shall be automatically included in the Spark
Intellectual Property licensed to Genable Licensee pursuant to Paragraph 3.1 of this Agreement. 

  

	 	3.8	Genable’s rights under this Agreement with respect to Patent Rights licensed by Spark from CHOP shall be subject to Genable’s satisfaction, as a sublicensee of Spark under the CHOP License Agreement, of the
obligations set forth on Appendix B. Such obligations shall be binding upon Genable with respect to the Patent Rights licensed by Spark from CHOP to the extent Spark is required to impose such obligations on its sublicensees pursuant to the CHOP
License Agreement. For the avoidance of doubt, (a) the “Company” referred to in the language from the CHOP License Agreement quoted in Appendix B is Spark, but under the CHOP License Agreement Spark is obligated to impose its
obligations under the quoted provisions on its sublicensees to the same extent such obligation apply to Spark and (b) the Patent Rights identified in Appendix A are licensed by Spark from CHOP and are therefore subject to this
Paragraph 3.8. 

  

	4.	SUBLICENSING 

  

	 	4.1	Genable may exercise its rights under this Agreement by an Affiliate and any action of such Affiliate shall be deemed for all purposes to be an action of Genable. 

 

	 	4.2	Genable may enter into sublicensing agreements for the Licensed Products to and only to the extent of any license granted to Genable under this Agreement. 

 

	 	4.3	Genable agrees that any sublicenses granted by it shall contain provisions which are equivalent to Paragraphs 3.8, 4.5 and 7.1 of this Agreement. 

 

	 	4.4	Genable’s execution of a sublicense agreement will not relieve Genable of any of its obligations under this Agreement. Genable is primarily liable to Spark for any act or omission of an Affiliate or sublicensee of
Genable that would be a breach of this Agreement if performed or omitted by Genable, and Genable will be deemed to be in breach of this Agreement as a result of such act or omission. 

 

	 	4.5	Termination of the license granted to Genable by Spark under this Agreement will terminate all sublicenses which may have been granted by Genable. 

  
 6 

	5.	PAYMENTS 

  

	 	5.1	In consideration of the license of the Spark Intellectual Property, Genable shall pay to Spark [**], due within [**] days of the Effective Date. 

 

	 	5.2	In further consideration of the license of the Spark Intellectual Property, Genable shall pay to Spark the applicable milestone payments listed in the table below within [**] days after each milestone event for the
first Licensed Product is achieved by Genable, its Affiliates, licensees or sublicensees: 

  

			
	[**]	  	[**]
	[**]	  	[**]
	[**]	  	[**]

  

	 	5.3	For the avoidance of doubt: 

  

	 	(i)	each of the milestone payments set out in Paragraph 5.2 shall be payable no more than once; 

  

	 	(ii)	all clinical milestones refer to [**]; 

  

	 	(iii)	the Licensee shall have no obligation to pay any milestones other than those listed in Paragraph 5.2; and 

  

	 	(iv)	none of the foregoing milestones may be skipped. If a milestone is not achieved for any reason, but the subsequent milestone is achieved, the prior unachieved milestone shall be deemed achieved and the corresponding
milestone payment shall be payable with the milestone payment for the achieved subsequent milestone. In addition, with respect to the [**] milestone, if a [**]. 

  

	 	5.4	In consideration of the license of the Spark Intellectual Property, the royalty payable by Genable to Spark on Net Sales of the Licensed Product shall be calculated by reference to the table set out below:

  

			
	 Annual Net Sales
	  	 Applicable Royalty Rate

	First $[**]	  	[**]% of Net Sales
	Increments above $[**]	  	[**]% of Net Sales

  
 7 

	 	5.5	Sublicense Revenues: 

  

	 	5.5.1	For any licenses or sublicenses granted by Genable during the term of this Agreement, Genable shall pay to Spark the milestones and royalties according to this Agreement on milestone achievements and Net Sales of the
Licensed Products by Affiliates, licensee(s) and sublicensee(s) as if such milestone achievements and sales were milestone achievements and Net Sales from Licensed Products by Genable. 

 

	 	5.5.2	For the avoidance of doubt, any payments received by Genable from a licensee or sublicensee such as for the funding of research and/or development, or for the granting of any commercialization rights including any
milestone or other upfront payments, shall not be considered to be part of Net Sales. 

  

	 	5.6	No multiple royalties shall be payable because any Licensed Products are covered by more than one patent, or patent application of the Patent Rights. 

 

	 	5.7	On sales of Licensed Products by Genable or Affiliates, licensees or sublicensees made other than in an arm’s-length transaction, the value of the Net Sales attributed under this Article 5 to such a transaction
shall be that which would have been received in an arm’s-length transaction, based on sales of like quantity and quality products on or about the time of such transaction. 

 

	 	5.8	The payments due to Spark from Genable pursuant to Paragraphs 5.1 and 5.2 shall be payable as set forth in such Paragraphs. Royalty payments due to Spark from Genable pursuant to Paragraph 5.3 shall be payable within
[**] days of the end of the calendar quarter in which the applicable Net Sales occur. 

  

	 	5.9	Payments made by Genable to Spark shall be delivered by wire transfer in U.S. Dollars (unless otherwise specifically agreed by the parties in writing) to the designated bank account of Spark in accordance with such
timely written instructions as Spark shall from time to time provide. 

  

	6.	PATENT FILING, PROSECUTION, AND MAINTENANCE 

  

	 	6.1	Spark shall control the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the Patent Rights and shall furnish copies of relevant patent-related documents to
Genable. 

  

	 	6.2	Spark shall have sole discretion whether to prepare, file, prosecute and maintain any and all patent applications or patents included in the Patent Rights in the Territory. 

 

	 	6.3	If at any time during the term of this Agreement Genable opposes or contests the grant or validity of the Patent Rights licensed herein, or any claims thereof, Spark will be entitled to terminate the license granted to
Genable under Paragraph 3.1 of this Agreement, upon thirty (30) days’ prior written notice to Genable. 

  

	7.	RECORD KEEPING 

  

	 	7.1	 Genable agrees to keep accurate and correct records of Licensed Products appropriate to determine the amount of royalties due Spark. Such records
shall be 

  
 8 

	 	
retained for at least [**] years following a given reporting period. The records shall be available, [**], during normal business hours for inspection at the expense of Spark by an accountant or
other designated auditor selected by Spark (and reasonably acceptable to Genable) for the sole purpose of verifying reports and payments hereunder. Genable may only object to an auditor selected by Spark for good cause shown. The accountant or
auditor shall only disclose to Spark information relating to the accuracy of reports and payments made under this Agreement. If an inspection shows an underreporting or underpayment in excess of [**] percent ([**]%) for any twelve (12) month
period, then Genable shall reimburse Spark for the reasonable cost of the inspection at the time Genable pays the unreported royalties, including any late charges as required by Paragraph 7.2 of this Agreement. All payments required under this
Paragraph 7.1 shall, if not disputed by Genable, be due within [**] days of the date Spark provides Genable notice of the payment due. 

  

	 	7.2	Late charges will be assessed by Spark on any undisputed overdue payments, and on all disputed overdue payments that are determined not to have been correctly disputed, at a rate of [**] percent ([**]%) per month. The
payment of such late charges shall not prevent Spark from exercising any other rights it may have as a consequence of the lateness of any payment. 

  

	8.	PERFORMANCE REQUIREMENTS AND REPORTS 

  

	 	8.1	Genable will use Commercially Reasonable Efforts to develop, bring to market and commercialize the Licensed Products through a diligent program of development, marketing and commercialization, in both [**]. Within [**]
of the Effective Date, Genable will prepare an outline development plan for developing and bringing the Licensed Product to market in both [**] (the “Commercial Development Plan”) and provide a copy to Spark. The Commercial
Development Plan may be changed by Genable from time to time based on medical, regulatory and commercial considerations then pertaining. 

  

	 	8.2	Genable shall report to Spark the date of the First Commercial Sale in each country in the Licensed Territory within [**] days of such occurrence. 

 

	 	8.3	Genable shall submit to Spark within [**] days after each calendar quarter ending March 31, June 30, September 30, and December 31 a royalty report setting forth for the preceding quarterly
period the amount of the Licensed Products sold by or on behalf of Genable or by an Affiliate, licensee or sublicensee in each country within the Licensed Territory, the Net Sales, and the amount of royalty or other payment accordingly due. With
each such royalty report, Genable shall submit payment of the earned royalties due. If no earned royalties are due to Spark for any reporting period, the written report shall so state. The royalty report shall be certified as correct by an
authorized officer of Genable and shall include a detailed listing of all deductions made under Paragraph 2.15 to determine Net Sales made under Article 6 to determine royalties due. 

 

	 	8.4	 Royalties due under Article 5 shall be paid in U.S. dollars. For conversion of foreign currency to U.S. dollars, the conversion rate shall be the New
York foreign exchange rate quoted in The Wall Street Journal on the day that the payment is due. Any loss of exchange, value taxes, or other expenses incurred in the transfer

  
 9 

	 	
or conversion to U.S. dollars shall be paid entirely by Genable. The royalty report required by Paragraph 8.3 of this Agreement shall accompany each such payment and a copy of such report shall
also be mailed to Spark at its address for notices indicated in Paragraph 14.6 of this Agreement. 

  

	 	8.5	All plans and reports required by this Article 8 and marked confidential by Genable shall be treated by Spark as commercial and financial information obtained from a person and as privileged and confidential.

  

	 	8.6	If applicable laws of Ireland require that taxes be withheld with respect to any payments by Genable to Spark under this Agreement, Genable will: (a) deduct those taxes from the remittable payment, (b) pay the
taxes to the proper taxing authority, and (c) send evidence of the obligation together with proof of tax payment to Spark on a timely basis following that tax payment. If Spark is a taxable entity in the United States and is therefore entitled
to the benefits of the double taxation treaty between Ireland and the United States, and Spark provides Genable with a Form 6166 from the United States Internal Revenue Service with respect to such taxable status, at or prior to the time of any
payment potentially subject to the Irish withholding tax is made hereunder, then payments made by Genable to Spark hereunder shall be made without withholding tax; provided that, if such double taxation treaty is modified after the Effective Date so
that payments to Spark hereunder are subject to withholding taxes, Genable shall give notice to Spark of such change and shall pay to Spark such additional amount as may be necessary so that Spark shall receive, after deduction of such withholding
tax, the amount which Spark would have received in the absence of such withholding tax less [**] percent ([**]%) of the withholding tax amount (i.e., the Parties [**] percent ([**]%) of the withholding tax amount). If Spark is not able to meet the
above criteria for withholding tax treaty benefits (e.g., by ceasing to be, or by assigning its interest in this Agreement to an entity that is not, a taxable entity in the United States entitled to the benefits of the double taxation treaty between
Ireland and the United States), then Genable shall make payments less any required withholding tax, and such withholding taxes required under Irish law shall be borne solely by Spark. If Genable or any successor or assign of Genable makes any
payment to Spark hereunder in a manner that subjects such payment to a withholding tax obligation under the laws of any jurisdiction other than those of Ireland (i.e., either by such entity being or becoming domiciled in any jurisdiction other than
Ireland or by such entity making any payment to Spark from a jurisdiction outside of Ireland), then Genable shall give notice to Spark of such requirement and shall pay to Spark such additional amount as may be necessary so that Spark shall receive,
after deduction of such withholding tax, the amount which Spark would have received in the absence of such withholding tax. Each Party agrees to cooperate with the other Party in claiming refunds or exemptions from such deductions or withholdings
under any relevant agreement or treaty which is in effect (e.g., Genable shall not withhold Irish withholding tax without first confirming with Spark that Spark is not able to provide the documentation of its taxable status as described above). The
Parties shall discuss and cooperate regarding applicable mechanisms for minimizing such taxes to the extent possible in compliance with applicable law. In addition, the Parties shall cooperate in accordance with applicable law to minimize indirect
taxes (such as value added tax, sales tax, consumption tax and other similar taxes) in connection with this Agreement. 

  
 10 

	9.	INFRINGEMENT AND PATENT ENFORCEMENT 

  

	 	9.1	Spark and Genable agree to notify each other promptly of each infringement or possible infringement of the Patent Rights within the Licensed Field, as well as any facts which may affect the validity, scope, or
enforceability of the Patent Rights of which either Party becomes aware. 

  

	 	9.2	If infringement of the Patent Rights occurs, or if infringement may occur, Spark shall have sole discretion to charge a third party with infringement and shall have the sole discretion to institute an infringement
action. Spark may decline to charge infringement or institute an infringement action at Spark’s sole discretion. If Spark elects to charge a third party with infringement or elects to institute an infringement action, Spark shall bear the cost
of such action and shall retain all recovery. 

  

	 	9.3	If Spark elects not to charge a third party with infringement or elects not to institute an infringement action (such decision to be made promptly by Spark), Genable shall, subject to the terms of the CHOP License
Agreement with respect to Patent Rights licensed from CHOP, if applicable, have the right (but not the obligation) to bring such suit. If Genable so elects to charge a third party with infringement or to institute an infringement action, Genable
shall bear all costs in such action or any resulting defense or declaratory judgment action for non-infringement, invalidity or unenforceability of the Patent Rights and Genable shall not settle any such action in a manner that imposes any liability
on Spark or imposes a material detriment to any Patent Rights without express permission by Spark (such permission not to be unreasonably withheld, delayed or conditioned). If Genable elects to charge a third party with infringement or elects to
institute an infringement action, Genable shall, after payment to CHOP of any share thereof payable to CHOP pursuant to the CHOP License Agreement with respect to Patent Rights licensed from CHOP, if applicable, retain all recovery.

  

	 	9.4	In any action instituted by a third party to contest the validity or unenforceability of the Patent Rights, Spark shall have the sole discretion to defend such action at its own expense. If Spark desires not to defend
said action, Genable shall, subject to the terms of the CHOP License Agreement with respect to Patent Rights licensed from CHOP, if applicable, have the right (but not the obligation) to defend such suit. If Genable so decides to defend them such
defense shall be conducted by Genable at Genable’s sole expense and Genable shall not settle any such action in a manner that imposes any liability on Spark or imposes any material detriment to any Patent Rights without express permission by
Spark (such permission not to be unreasonably withheld, delayed or conditioned). If Genable elects to defend such an action, Genable shall, after payment to CHOP of any share thereof payable to CHOP pursuant to the CHOP License Agreement with
respect to Patent Rights licensed from CHOP, if applicable, retain all recovery. 

  

	 	9.5	In any litigation under this Article 9, either Party, at the request and sole expense of the other Party, will cooperate to the fullest extent reasonably possible. This Paragraph 9.5 will not be construed to require
either Party to undertake any activities, including legal discovery, at the request of any third party, except as may be required by lawful process of a court of competent jurisdiction. If, however, either Party is required to undertake any
activity, including legal discovery, as a right of lawful process of a court of competent jurisdiction, then the litigating Party will pay all expenses incurred by the other Party. 

  
 11 

	10.	WARRANTIES AND INDEMNIFICATION 

  

	 	10.1	Spark and Genable offer no warranties other than those specified in this Article 10. 

  

	 	10.2	Spark represents and warrants to Genable that, as of the Effective Date: 

  

	 	(a)	the issued Patent Rights are not invalid or unenforceable, to Spark’s present knowledge, 

  

	 	(b)	Spark has the right to grant to Genable the license specified in Article 3 of this Agreement, 

  

	 	(c)	Spark owns or has a valid license under any United States and foreign patent applications or patents corresponding to the Patent Rights, 

 

	 	(d)	this Agreement has been duly executed and delivered by a duly authorized officer of Spark and constitutes the valid and legally binding obligations of Spark enforceable against Spark according to its terms except as
enforceability of this Agreement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting creditors’ rights generally, and 

 

	 	(e)	no proceedings or written notices have been received by Spark from any third party alleging that the Spark Intellectual Property infringes any third party intellectual property. 

 

	 	10.3	Spark further represents and warrants to Genable as of the Effective Date: 

  

	 	(a)	the CHOP License Agreement is valid and in full force and effect; and 

  

	 	(b)	there are no existing or claimed defaults by Spark, and to Spark’s best knowledge, by CHOP under the CHOP License Agreement, and no event, act or omission has occurred that (with or without notice, lapse of time or
the happening or occurrence of any other event) would result in a default under the CHOP License Agreement. 

  

	 	10.4	Spark covenants to Genable that during the Term: 

  

	 	(a)	Spark will fully comply with all of the terms and conditions of the CHOP License Agreement and will reasonably enforce its rights under the CHOP License Agreement and Spark will not assign its rights under the CHOP
License Agreement except where this Agreement is also being assigned in accordance with Paragraph 14.7, provided that, Spark shall not be responsible for any failure to comply with the CHOP License Agreement that results from Genable’s
failure to fully comply with all of the terms and conditions of this Agreement; and 

  
 12 

	 	(b)	Spark will keep Genable reasonably informed with respect to Spark’s transactions, arrangements and business under the CHOP License Agreement that relate to Genable and/or the transactions contemplated hereunder,
and Spark shall provide Genable with any written notices delivered by Spark or CHOP as appropriate thereunder that relate to Genable and/or the obligations or rights under this Agreement that may adversely affect Genable; and 

 

	 	(c)	Spark shall not amend, modify, or waive any of its rights under the CHOP License Agreement, if such amendment, modification or waiver would adversely affect Genable and/or Genable’s rights and/or obligations or
under this Agreement, without the prior written consent of Genable. For the avoidance of doubt, Spark shall not terminate any of its rights under the CHOP License Agreement without the prior written consent of Genable if such termination would
adversely affect Genable and/or Genable’s rights and/or obligations or under this Agreement. 

  

	 	10.5	Save for the warranties set forth in Paragraphs 10.2 and 10.3, Spark does not warrant the validity of the Patent Rights and makes no representations whatsoever with regard to the scope of the Patent Rights, or that the
Patent Rights may be exploited without infringing other patents or other intellectual property rights of third parties. 

  

	 	10.6	NO WARRANTIES, EXPRESS OR IMPLIED, ARE OFFERED BY SPARK AS TO THE FITNESS FOR ANY PURPOSE OF THE MATERIALS OR INFORMATION PROVIDED TO GENABLE UNDER THIS AGREEMENT, OR THAT THE SPARK INTELLECTUAL PROPERTY MAY BE
EXPLOITED WITHOUT INFRINGING OTHER THIRD PARTY RIGHTS. GENABLE ACCEPTS THE SPARK INTELLECTUAL PROPERTY, INFORMATION AND THE MATERIALS “AS IS,” AND SPARK DOES NOT OFFER ANY GUARANTEE OF ANY KIND. 

 

	 	10.7	Spark does not represent that it will commence legal actions against third parties infringing the Spark Intellectual Property. 

  

	 	10.8	Genable warrants that to the best of its knowledge it has the necessary patent rights, licenses and other intellectual property required to develop GT038. 

 

	 	10.9	Genable represents and warrants to Spark that this Agreement has been duly executed and delivered by a duly authorized officer of Genable and constitutes the valid and legally binding obligations of Genable enforceable
against Genable according to its terms except as enforceability of this Agreement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting creditors’ rights generally. 

 

	 	10.10	 Genable shall indemnify and hold Spark, its employees, affiliates, agents, and consultants harmless from and against all liability, demands, damages,
expenses, and losses, including but not limited to, death, personal injury, illness, or property damage to the extent arising in connection with any activities related to Licensed Products under this Agreement by Genable, its directors, employees,
agents and its sublicensees, including any of their customers, patients, or end-users, including, without limitation, the research, development, importation, exportation, 

  
 13 

	 	
design, manufacture, distribution, offering for sale, sale, or use of any Licensed Products or in connection with any end user or clinical trial in which Genable participates utilizing Licensed
Products, except to the extent arising (i) in connection with any breach of this Agreement by Spark, or (ii) from the gross negligence or willful misconduct of Spark, its employees, affiliates, agents, and consultants. 

 

	 	10.11	Spark shall indemnify and hold Genable, its employees, affiliates, agents, and consultants harmless from and against all liability, demands, damages, expenses, and losses arising in connection with (i) any breach
of this Agreement by Spark, or (ii) the gross negligence or willful misconduct of Spark, its employees, affiliates, agents, and consultants. 

  

	 	10.12	Each Party shall when seeking an indemnity pursuant to Paragraphs 10.9 and 10.10 shall: 

  

	 	(a)	fully and promptly notify the indemnifying Party of any claim or proceedings, or threatened claim or proceedings; 

  

	 	(b)	permit the indemnifying Party to take full control of such claim or proceedings, with counsel of such indemnifying Party’s choice, provided that the indemnifying Party shall reasonably and regularly consult with
the indemnified Party in relation to the progress and status of such claim or proceedings; 

  

	 	(c)	co-operate in the investigation and defense of such claim or proceedings; and 

  

	 	(d)	take all reasonable steps to mitigate any loss or liability in respect of any such claim or proceedings. 

The indemnifying Party may settle a claim on terms which provide only for monetary relief and do not include any admission of liability. Save
as aforesaid, neither the indemnifying Party nor the Party to be indemnified shall acknowledge the validity of, compromise or otherwise settle any claim without the prior written consent of the other, which shall not be unreasonably withheld or
delayed. 
  

	 	10.13	NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, NEITHER SPARK NOR GENABLE SHALL BE LIABLE TO THE OTHER BY REASON OF ANY REPRESENTATION OR WARRANTY, CONDITION OR OTHER TERM OR ANY DUTY OF COMMON LAW, OR UNDER
THE EXPRESS TERMS OF THIS AGREEMENT, FOR ANY INDIRECT, CONSEQUENTIAL, SPECIAL, INCIDENTAL OR PUNITIVE LOSS OR DAMAGE (OR FOR ANY LOSS OF CURRENT OR FUTURE PROFITS, LOSS OF ENTERPRISE VALUE) LOSS OF USE, LOSS OF SAVINGS OR ANTICIPATED SAVING, LOSS OF
GOODWILL, LOSS OF DATA OR LOSS OF BUSINESS OR ANTICIPATED BUSINESS, WHETHER OCCASIONED BY THE NEGLIGENCE OF THE RESPECTIVE PARTIES, THEIR EMPLOYEES OR AGENTS OR OTHERWISE. 

 

	 	10.14	Nothing in this Agreement shall have the effect of excluding or limiting any liability for death or personal injury caused by negligence or for fraud. 

  
 14 

	11.	CONFIDENTIALITY 

  

	 	11.1	Each Party undertakes with the other that it shall keep, and that it shall procure that its respective directors and employees keep secret and confidential all know-how, technical, business and other information that
has the quality of confidentiality and that is communicated to it by the other Party under or in respect of this Agreement or acquired from any other Party as a result of this Agreement (“Confidential Information”) and shall not
disclose the same or any part of the same to any person whatsoever SAVE THAT either Party may disclose Confidential Information to its Affiliates and sublicensees and any of its directors, employees or consultants who are directly or indirectly
legitimately involved with the Spark Intellectual Property and its exploitation and who require the said Confidential Information for the purposes of the said involvement. 

 

	 	11.2	The non-disclosure provision of Paragraph 11.1 shall not apply to: 

  

	 	(a)	Confidential Information in the public domain otherwise than by breach of this Agreement; 

  

	 	(b)	Confidential Information in the lawful possession of a Party prior to disclosure by any other Party as evidenced by written records; 

 

	 	(c)	Confidential Information that was created independent of disclosure as evidenced by written records; or 

  

	 	(d)	Confidential Information obtained from a third party who is free to divulge the same. 

  

	 	11.3	The obligations of each Party under this Article 11 shall continue in force notwithstanding the termination of this Agreement. 

  

	 	11.4	Any Confidential Information disclosed by the disclosing Party shall be used by the receiving Party exclusively for the purposes of fulfilling the receiving Party’s rights and obligations under this Agreement and
for no other purpose. 

  

	 	11.5	A Party (the “Required Party”) will be entitled to make a disclosure or public statement concerning the existence, subject matter or any term of this Agreement, or to disclose Confidential Information
that the Required Party is required to make or disclose pursuant to: 

  

	 	(a)	a valid order of a court or governmental authority; or 

  

	 	(b)	any other requirement of law or any securities or stock exchange; 

 provided that if the
Required Party becomes legally required to make such announcement, public statement or disclosure hereunder, the Required Party shall (to the extent possible) give the other Party prompt notice of such fact to enable the other Party to seek a
protective order or other appropriate remedy concerning any such announcement, public statement or disclosure, including confidential treatment and/or appropriate redactions. 
  

	 	11.6	The Required Party shall fully co-operate with the other Party in connection with that other Party’s efforts to obtain any such order or other remedy. If any such order or other remedy does not fully preclude
announcement, public statement or disclosure, the Required Party shall make such announcement, public statement or disclosure only to the extent that the same is legally required. 

  
 15 

	12.	TERM AND TERMINATION 

  

	 	12.1	This Agreement is effective beginning with the Effective Date and shall extend on a country-by-country basis until the later of a) the date of the expiration of the last to expire of the Patent Rights in the country of
sale or the country of manufacture or b) the tenth anniversary of the First Commercial Sale in the country of sale, unless sooner terminated as provided in this Article 12. 

 

	 	12.2	Upon termination of this Agreement, Genable’s rights under Article 3 of this Agreement shall cease, effective immediately. On a country-by-country basis, after this Agreement has expired pursuant to Paragraph 12.1,
if this Agreement shall not have earlier terminated, Genable’s license in such country of the Territory shall remain in force on a fully paid-up, non-royalty-bearing basis, provided, however, that Genable may still have obligations to Spark in
countries in which this Agreement has not expired. 

  

	 	12.3	In the event that Genable is in material default in the payment of any money to Spark under this Agreement, and if the default has not been remedied within [**] days after the date of notice in writing of such default,
Spark may terminate this Agreement by written notice, provided that, if Genable in good faith disputes any such amount, provides notice of such dispute to Spark, institutes dispute resolution pursuant to Article 13 and pays all undisputed amounts
prior to the end of such [**] day period, this Agreement shall not terminate if Genable pays all amounts finally determined to be payable in such dispute resolution within [**] days after such final determination. In the event that Genable is in
material default in the performance of any other obligations under this Agreement, and if the default has not been remedied within [**] days after the date of notice in writing of such default, Spark may terminate this Agreement by written notice.
Spark shall also have the unilateral right and option to terminate this Agreement under Paragraph 6.4 upon [**] days prior notice to Genable. 

  

	 	12.4	In the event that Genable becomes insolvent, files a petition in bankruptcy, has such a petition filed against it, determines to file a petition in bankruptcy, or receives notice of a third party’s intention to
file an involuntary petition in bankruptcy, Genable shall immediately notify Spark in writing and Spark shall thereupon have the right to terminate this Agreement upon thirty (30) days’ notice to Genable. 

 

	 	12.5	Genable shall have a unilateral right to terminate this Agreement and/or any licenses in any country without cause by giving Spark ninety (90) days prior written notice to that effect. In the event that Spark
becomes insolvent, files a petition in bankruptcy, has such a petition filed against it, determines to file a petition in bankruptcy, or receives notice of a third party’s intention to file an involuntary petition in bankruptcy, Spark shall
immediately notify Genable in writing and Genable shall thereupon have the right to terminate this Agreement upon thirty (30) days’ notice to Spark. 

  

	 	12.6	 Upon termination of this Agreement for any reason, Genable, its Affiliates, licensees and sublicensees shall cease all development, use, distribution,
and sale of Licensed Products, provided however, that Genable and its Affiliates, licensees and sublicensees shall be permitted for a period not exceeding [**] 

  
 16 

	 	
months to exhaust their stocks of the Licensed Products, provided that this Agreement has not been terminated by Spark due to a breach of this Agreement by Genable or an Affiliate, licensee or
sublicensee or under Paragraph 6.3 of this Agreement, and any such post-termination sales by Genable, its Affiliates, licensees and sublicensees shall be subject to a surviving royalty obligation under Paragraph 5.4. 

 

	 	12.7	Within [**] days of the final sale of Licensed Product under this Article 12, a final report shall be submitted by Genable together with any royalty payments or other amounts due to Spark. 

 

	 	12.8	Termination of this Agreement will not relieve any party from any obligation that has accrued prior to termination. 

  

	 	12.9	The following provisions of this Agreement shall survive termination: Section 4.5, Article 7, Sections 8.3 - 8.6, Sections 10.10 - 10.14, Article 11, Sections 12.2,12.6 - 12.9, 14.5, 14.9 and 14.13.

  

	13.	DISPUTES 

  

	 	13.1	If a dispute arises which cannot be resolved in the normal course of events, any Party to the dispute may give notice in writing to the others specifying the subject matter of the dispute and its proposal for its
resolution. The Parties must procure that the dispute is considered by their respective authorized representatives and that such authorized representatives use all reasonable endeavors, in good faith, to resolve the dispute within [**] days of the
date of the notice specifying the dispute. If the authorized representatives reach agreement on the matter in dispute in the period specified in this Paragraph 13.1, the Parties shall procure that their respective representatives sign a joint
memorandum to that effect recording the resolution and procure that such agreement is fully and promptly carried into effect. 

  

	 	13.2	If the authorized representatives fail to reach agreement, any Party may refer the matter to the Chief Executive Officers of the Parties (together the “Senior Officers”). The Parties shall respectively procure
that the Senior Officers attempt in good faith to resolve the dispute. If the Senior Officers reach agreement on the matter in dispute within [**] days of the dispute being referred to them (or such other period as the Parties may mutually agree in
writing) the Parties shall procure that their respective Senior Officers shall sign a joint memorandum to that effect recording the resolution and procure that such agreement is promptly and fully carried into effect. 

 

	 	13.3	The dispute resolution procedure shall have been exhausted if the matter in dispute: 

  

	 	(a)	has not been resolved in accordance with Paragraph 13.1 within the relevant period and is not referred to the Senior Officers within the relevant period; or 

 

	 	(b)	where it is so referred, has not been resolved in accordance with Paragraph 13.2 within the relevant period. 

  
 17 

	 	13.4	For the avoidance of doubt, the fact that the dispute resolution procedure has been exhausted without resolution shall not prevent the Parties from agreeing that the dispute be referred to an independent alternative
form of dispute resolution and/or to arbitration. 

  

	 	13.5	The foregoing provisions shall not prevent either Party from commencing legal proceedings or applying to the court for injunctive or other interim relief at any time. 

 

	 	13.6	Any controversy or claim related to or arising out of this Agreement (other than a patent dispute) shall be settled by arbitration conducted on a confidential basis under the Commercial Arbitration Rules of the
International Centre for Dispute Resolution (“ICDR”) in effect at the time of the arbitration (“Rules”). Any arbitration shall be held in Manhattan, New York before one disinterested arbitrator selected by mutual agreement of the
Parties; provided, however, that if the Parties are unable to agree on the arbitrator within [**] days, the arbitrator shall be appointed in accordance with the Rules. Any Party desiring arbitration shall serve on the other Party pursuant to
Section 13.6 and the regional case management center of the ICDR administering cases for such location in accordance with the aforesaid Rules, its notice of intent to arbitrate (“Arbitration Notice”). All arbitrations shall be
administered by the ICDR. 

  

	 	13.7	The arbitrator shall have no authority to award damages expressly precluded under this Agreement. The award of the arbitrator shall be final and binding upon the Parties and judgment upon such award may be entered and
enforced in any court of competent jurisdiction. Unless the arbitrator for good cause determines otherwise, the costs and expenses of the arbitrator shall be shared equally by the Parties and each Party will bear its own attorneys’ fees and
other costs associated with the arbitration proceeding. If court proceedings to stay litigation or compel arbitration are necessary, the Party that unsuccessfully opposes such proceedings will pay all associated costs, expenses and attorneys’
fees that are reasonably incurred by the other Party. 

  

	14.	GENERAL PROVISIONS 

  

	 	14.1	Neither Party may waive or release any of its rights or interests in this Agreement except in writing. The failure of either Party to assert a right hereunder or to insist upon compliance with any term or condition of
this Agreement shall not constitute a waiver of that right by such Party or excuse a similar subsequent failure to perform any such term or condition by Genable. 

  

	 	14.2	This Agreement, together with the Manufacturing Agreement and Development Agreement, constitutes the entire agreement between the Parties relating to the subject matter, and all prior negotiations, representations,
agreements, and understandings are merged into, extinguished by, and completely expressed by such agreements. 

  

	 	14.3	The provisions of this Agreement are severable, and in the event that any provision of this Agreement shall be determined to be invalid or unenforceable under any controlling body of law such determination shall not in
any way affect the validity or enforceability of the remaining provisions of this Agreement. 

  
 18 

	 	14.4	If either Party desires a modification to this Agreement, the Parties shall, upon reasonable notice of the proposed modification by the Party desiring the change, confer in good faith to determine the desirability of
such modification. No modification will be effective until a written amendment is signed by the signatories to this Agreement or their designees. 

  

	 	14.5	The construction, validity, performance, and effect of this Agreement shall be governed by the Laws of the State of New York and, subject to Article 13, any and all actions or proceedings relating to this Agreement
shall be brought and pursued exclusively in the federal or state courts sitting in United States District Court for the Southern District of the State of New York. 

 

	 	14.6	Any notice required to be given under this Agreement shall be in writing and shall be delivered personally, or sent by pre-paid post or recorded delivery or by commercial courier, to each Party required to receive the
notice at its address as set out below: 

 Spark: 

Spark Therapeutics, LLC 
 3501
Civic Center Blvd., 5th Floor 
 Philadelphia, PA 19104 

USA 
 Attention: Jeffrey D.
Marrazzo, CEO 
 Genable: 

Genable Technologies Limited 

c/o Delta Partners 
 Media
House, South County Business Park 
 Leopardstown, Dublin 18 

Ireland 
 Attention: Jason
Loveridge, CEO 
 or as otherwise specified by the relevant Party by notice in writing to each other Party. 

Any notice shall be deemed to have been duly received: 
  

	 	(i)	if delivered personally, when left at the address and for the contact referred to in this Paragraph 14.6, or 

  

	 	(ii)	if delivered by commercial courier, on the date and at the time that the courier’s delivery receipt is signed. 

A notice required to be given under this Agreement shall not be validly given if sent by email. The provisions of this Paragraph 14.6 shall
not apply to the service of any proceedings or other documents in any legal action. 
  

	 	14.7	This Agreement, or any obligations of a party under this Agreement, may not be assigned except as expressly provided in this Agreement. This Agreement may be assigned by either Party as part of a sale or transfer of
substantially the entire business of the assigning Party relating to operations which concern this Agreement, provided that the assigning Party notifies the other Party in writing within [**] days of any assignment of this Agreement by the assigning
Party. 

  
 19 

	 	14.8	Genable acknowledges that it is subject to and agrees to abide by the United States laws and regulations (including the Export Administration Act of 1979 and Arms Export Control Act) controlling the export of technical
data, computer software, laboratory prototypes, biological material, and other commodities. The transfer of such items may require a license from the relevant Agency of the U.S. Government or written assurances by Genable that it shall not export
such items to certain foreign countries without prior approval of such agency. Spark neither represents that a license is not required or that, if required, it shall be issued. 

 

	 	14.9	Promptly after execution of this Agreement, the Development Agreement and the Manufacturing Agreement, the Parties shall issue the press release attached hereto as Appendix C. Neither Party shall issue any press
releases or public disclosure relating to this Agreement, other than the aforementioned initial press release and any public disclosures that may be required pursuant to applicable securities laws and regulations, without the prior written consent
of the other Party, which consent shall not be unreasonably withheld or delayed. Neither Party shall use the name or logo of the other Party, and Genable shall not use the name of past or present Spark employees, in any advertising, promotional or
sales activities without prior written consent obtained from the other Party in each separate case, except as otherwise provided in this Agreement. 

  

	 	14.10	Neither Party to this Agreement shall be liable for delay in the performance of any of its obligations hereunder if such delay results from causes beyond its reasonable control, including, without limitation, acts of
God, fires, strikes, acts of war, or intervention of a government authority, non-availability of raw materials, but any such delay or failure shall be remedied by such Party as soon as practicable. 

 

	 	14.11	This Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which when taken together shall constitute this Agreement. 

 

	 	14.12	Both Parties are independent contractors under this Agreement. Nothing herein contained shall be deemed to create an employment, agency, joint venture or partnership relationship between the Parties hereto or any of
their agents or employees. Neither Party shall have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect
whatsoever. 

  

	 	14.13	During the term of this Agreement and for a period of [**] months thereafter, neither Party shall solicit an employee of the other Party who is or has been involved in the performance or oversight of any development,
manufacturing or regulatory activity with respect to any Licensed Product to terminate his or her employment and accept employment or work as a consultant with the soliciting Party. Notwithstanding the foregoing, nothing herein shall restrict or
preclude the Parties’ right to make generalized searches for employees by way of a general solicitation for employment placed in a trade journal, newspaper or website. 

 

	 	14.14	No provision of this Agreement is intended to confer any rights, benefits, remedies, obligations, or liabilities hereunder upon any third party beneficiary or on any person other than the Parties and their respective
affiliates, successors and assigns. 

  
 20 

 IN WITNESS WHEREOF, duly authorized representatives of the Parties have duly executed this Agreement to be
effective as of the Effective Date. 
 SPARK THERAPEUTICS, LLC: 

 

					
	 /s/ Jeffrey D. Marrazzo
	 		  	 March 18, 2014

	Signature of Authorized Official	 		  	Date
			
	 Jeffrey D. Marrazzo
	 		  	
	Printed Name	 		  	
			
	 President & CEO
	 		  	
	Title	 		  	
			
	GENABLE TECHNOLOGIES LIMITED:	 		  	
			
	 /s/ Jason Loveridge
	 		  	 18 March 2014

	Signature of Authorized Official	 		  	Date
			
	 Jason Loveridge
	 		  	
	Printed Name	 		  	
			
	 CEO
	 		  	
	Title	 		  	

  
 21 

 APPENDIX A — Patent(s) or Patent Application(s) and Confidential Information 

 

					
	 Spark

Tech ID
Number
	  	 Patent
Application/
Publication/
Granted No.
	  	 Title

	[**]	  	[**]	  	[**]
	[**]	  	[**]	  	[**]

 [**] 
 Intellectual property
owned or controlled by Spark with respect to: 
 [**]. 

  
 22 

 APPENDIX B - CHOP License Agreement Terms Applicable to Genable 

Provisions quoted below in this Appendix B are copied verbatim from the CHOP License Agreement. Capitalized terms in language quoted below shall have the
meanings ascribed to them in the CHOP License Agreement and Paragraph cross-references therein shall refer to Paragraphs in the CHOP License Agreement. 

“4.4 In the event this Agreement terminates, and such termination is not the result of any failure by a sublicensee to comply with the terms of this
Agreement applicable to sublicensees, such sublicensee’s sublicense shall survive such termination in respect of the sublicensee’s exercise of such sublicense rights provided, however, that CHOP shall not be obligated in any manner to
perform any obligations of Company under the sublicense agreement beyond the granting of rights to the sublicensee with respect to the Patent Rights and Gene Therapy Know-How. 
  

... 
 5.1 CHOP retains the ability to research, make, have
made, practice, have practiced, and use CHOP Intellectual Property solely for its own research and/or educational purposes. In addition, all rights granted in this Agreement are expressly granted subject to the rights of the U.S. Government pursuant
to 35 U.S.C. Sections 200 et seq., as amended, (Patent Rights in Inventions Made with Federal Assistance) and the implementing regulations. 
 5.2 Company
agrees that if any Patent Rights claiming inventions were supported by funding from a U.S. government agency, products used or sold in the United States embodying such Patent Rights shall be manufactured substantially in the United States, unless a
written waiver is obtained in advance from the appropriate government agency. 
  
 ...

 7.1 Company agrees to keep, and to require its Affiliates and sublicensees to keep, accurate and correct records of Licensed Products under this
Agreement appropriate to determine the amount of royalties and payments due CHOP. Such records shall be retained for at least [**] years following a given reporting period. The records shall be made available, [**], at the request of CHOP during
normal business hours for inspection at the expense of CHOP by an accountant or other designated auditor selected by CHOP (and acceptable to Company) for the sole purpose of verifying reports and payments hereunder. Company may only object to an
auditor selected by CHOP for good cause shown. If an inspection shows an underreporting or underpayment in excess of [**] percent ([**]%) for any twelve (12) month period, then Company shall reimburse CHOP for the cost of the inspection at the
time Company pays the unreported royalties, including any late charges as required by this Agreement. All payments required under this Paragraph shall be due within [**] days of the date CHOP provides Company notice of the payment due. Late charges
will be assessed by CHOP on any undisputed overdue payments at a rate of [**] percent ([**]%) per month. The payment of such late charges shall not prevent CHOP from exercising any other rights it may have as a consequence of the lateness of any
payment. 
  
 ... 

8.1 CHOP shall control the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the Patent Rights and
shall furnish copies of relevant patent-related documents to Company. Notwithstanding this Paragraph 8.1, any opposition, validity challenge, interference, re-examination, reissue, derivation, supplemental examination, post-grant review,
inter-parties review proceedings, negotiations or claims, in any forum shall be handled in accordance with Paragraph 10.3. 

  
 23 

  
 ... 

10.1 CHOP and Company agree to notify each other promptly of each infringement or possible infringement of the Patent Rights, as well as any facts which may
affect the validity, scope, or enforceability of the Patent Rights of which either Party becomes aware. 
 10.2 Pursuant to this Agreement Company may a)
bring suit in its own name, at its own expense, and on its own behalf for infringement of presumably valid claims in the Patent Rights or misappropriation of Gene-Therapy Know-How; b) in any such suit, seek to enjoin infringement or misappropriation
and collect damages, profits, and awards of whatever nature recoverable for such infringement; and c) settle any claim or suit for infringement of the Patent Rights or misappropriation of Gene-Therapy Know-How. Company shall not settle any action
that imposes any liability on CHOP or concedes the invalidity, enforceability or non-infringement of any of the Patent Rights or CHOP Intellectual Property without the prior written consent of CHOP. If necessary or desirable to bring, maintain or
prove damages in any such action, Company may require that CHOP join such suit. Should CHOP be made a party to any such suit at the request of Company, Company shall reimburse CHOP for any costs, expenses, or fees, which CHOP incurs as a result of
such action. In all cases, Company agrees to keep CHOP reasonably apprised of the status and progress of any litigation. Before Company commences an infringement action, Company shall notify CHOP and give careful consideration to the views of CHOP.

 10.3 In the event that a declaratory judgment action alleging invalidity or non-infringement of any of the Patent Rights or contesting the Gene Therapy
Know-How rights (excluding any such action that is based on alleged misappropriation by CHOP of Gene Therapy Know-How) shall be brought against Company or CHOP or raised by way of counterclaim or affirmative defense in an infringement suit brought
by Company under Paragraph 10.2, pursuant to this Agreement, or any opposition, validity challenge, interference, re-examination, reissue, derivation, supplemental examination, post-grant review, inter-parties review proceedings, negotiations or
claims, in any forum relating to the Patent Rights, Company shall, subject to the penultimate sentence of this Paragraph 10.3a) defend or handle the suit or proceeding, at its own expense, for presumably valid claims in the Patent Rights; and b) in
any such suit or proceeding, ultimately seek to enjoin infringement and to collect damages, profits, and awards of whatever nature recoverable from the party bringing such suit or otherwise defend the validity and enforceability of the Patent
Rights. Company shall not settle any action that imposes any liability on CHOP or concedes the invalidity, enforceability or non-infringement of any of the Patent Rights or CHOP Intellectual Property without the prior written consent of CHOP. If
necessary or desirable to defend any such action, Company may require that CHOP join such suit. Should CHOP be made a party to any such suit at the request of Company, Company shall reimburse CHOP for any costs, expenses, or fees which CHOP incurs
as a result of such action. If Company elects not to initiate a defense against such declaratory judgment action, CHOP at its option, may do so at its own expense and CHOP shall retain all recoveries from any such suit. In all cases, Company agrees
to keep CHOP reasonably apprised of the status and progress of any litigation. 
  
 ...

 11.3 CHOP does not warrant the validity of the Patent Rights and makes no representations whatsoever with regard to the scope of the Patent Rights, or
that the Patent Rights may be exploited without infringing other patents or other intellectual property rights of third parties. 

  
 24 

 11.4 NO WARRANTIES, EXPRESS OR IMPLIED, ARE OFFERED BY CHOP AS TO THE FITNESS FOR ANY PURPOSE OF THE MATERIALS OR
INFORMATION PROVIDED TO COMPANY UNDER THIS AGREEMENT, OR THAT THE CHOP INTELLECTUAL PROPERTY MAY BE EXPLOITED WITHOUT INFRINGING OTHER THIRD PARTY PATENT RIGHTS. COMPANY ACCEPTS THE CHOP INTELLECTUAL PROPERTY, INFORMATION AND THE MATERIALS “AS
IS,” AND CHOP DOES NOT OFFER ANY GUARANTEE OF ANY KIND. 
 11.5 Except as otherwise set forth in Paragraphs 10.2 and 10.3, CHOP does not represent that
it will commence legal actions against third parties infringing the Patent Rights. 
  

... 
 12.5 CHOP reserves the right of 35 U.S.C. §203 to
terminate or modify this Agreement solely to the extent that such action is legally necessary to meet requirements of the applicable federal statutes or regulations and such requirements are not reasonably satisfied by Company. Within [**] days of
receipt of written notice of CHOP’S belief or notification from the government that it is legally necessary to modify or terminate this Agreement, Company shall, if Company disagrees with such assessment, notify CHOP of such disagreement
and the basis for Company’s position and this Agreement shall not be terminated or modified unless and until such disagreement is resolved in accordance with Paragraph 13.12 or by the exercise of the march-in-rights by the government. 

12.6 Within [**] days of termination or expiration of this Agreement, a final report and all accrued payments shall be submitted by Company. If this Agreement
is terminated under this Article 12, sublicenses may be converted to direct licenses with CHOP pursuant to Paragraph 4.4.” 

  
 25 

 APPENDIX C - Press Release 

 

			
	

	  	

	 Media Inquiries:
 Jessica
Rowlands
 202-729-4089

Jessica.Rowlands(S)fkhealth.com
	  	 Dr. Jason Loveridge
 + 33 674177812

jloveridge@genable.net

 Spark Therapeutics and Genable Technologies Announce Collaboration to Advance a Gene Therapy Treatment for a
Rare Form of Retinitis Pigmentosa 
 PHILADELPHIA, Penn., Mar. 18, 2014 — Spark Therapeutics and Genable Technologies announced today
that they have entered into a collaboration agreement for Genable’s lead therapeutic to treat rhodopsin linked autosomal dominant retinitis pigmentosa (RHO adRP), GT038. Under the terms of the collaboration, Genable will license certain
adeno-associated virus (AAV) vector manufacturing patents from Spark. The parties have entered into a broad agreement in which Spark will be the exclusive manufacturer for the product and provide development advice and expertise to Genable to help
in the ongoing development of GT038. Spark will receive milestone payments and royalties on future sales of GT038 as well as near-term revenue from the manufacture and supply of product. 

“We are excited to apply our deep expertise in AAV clinical development and manufacturing to augment Genable’s great work, and expand the number of
debilitating diseases of the eye that can be addressed through gene therapy,” said Jeffrey D. Marrazzo, Spark Therapeutics co-founder, president and CEO. 

Dr. Jason Loveridge, CEO of Genable Technologies commented “We have chosen Spark as our partner to advise, lend their experience and manufacture
GT038 based on their broad expertise in gene therapy. We see them as a world-class organization and we are excited to be advancing our novel therapy GT038 into the clinic”. 

GT038 is a potential treatment for rhodopsin (RHO)-linked autosomal dominant retinitis pigmentosa (adRP), an inherited retinal dystrophy that leads to
blindness in most cases. There is currently no approved pharmacologic treatment for adRP, which affects an estimated 30,000 patients worldwide. GT-038 utilizes AAV vectors with an established safety and efficacy profile to deliver RNA interference
(RNAi) molecules to suppress the expression of faulty and normal copies of RHO and restore normal gene expression. GT038 has been granted Orphan Drug Designation in both the USA and Europe. 

About Genable Technologies 
 Genable Technologies Ltd. is
a privately held, venture capital backed Dublin (Ireland) based bio-pharmaceutical company. The company is developing new gene therapies to treat “dominant” genetic diseases. The company has received significant support and investment form
Fountain Healthcare Partners, Delta Partners, Fighting Blindness Ireland, Foundation Fighting Blindness Clinical Research Institute (USA) and Enterprise Ireland. To learn more please visit www.genable.net 

  
 26 

 About Spark Therapeutics 

Spark Therapeutics is developing potentially curative, one-time gene therapy products to transform the lives of patients and re-imagine the treatment of
debilitating diseases. Spark’s lead gene therapy candidate, for RPE65-related blindness, is currently in Phase 3 clinical trials with the potential to be the first approved gene therapy in the U.S., and the first treatment to address the
significant unmet needs of patients living with blindness due to inherited retinal dystrophies. 
 Spark’s founding team includes scientists who led
the movement to develop gene therapy as a new treatment paradigm, establishing clinical proof of concept in the eye and liver and contributing key insights to the field that have resulted in a resurgence of industry interest in gene-based medicines.
In addition to the Phase 3 program in /?PE65-related blindness, the company has a Phase 1/2 program in hemophilia B, and preclinical programs to address neurodegenerative diseases and other inherited retinal dystrophies and hematologic disorders.
Spark has rights to a proprietary manufacturing platform that has an unparalleled track record of success in supporting clinical studies across diverse therapeutic areas and routes of administration. The company’s expertise across research,
clinical, regulatory and manufacturing builds on a legacy of innovation and excellence in gene therapy established by Spark’s team while at The Children’s Hospital of Philadelphia Center for Cellular and Molecular Therapeutics. To learn
more visit www.sparktx.com. 
 # # # 

  
 27EX-10.15

					
		 	 Confidential Materials omitted and filed separately with the

Securities and Exchange Commission. Double asterisks denote omissions.
	  	Exhibit 10.15

 MANUFACTURING AGREEMENT 

This Manufacturing Agreement (this “Agreement”) is made this
18th day of March, 2014 (the “Effective Date”) by and between Spark Therapeutics, LLC, a Delaware limited liability company with a principal address at 3501 Civic Center
Boulevard, Philadelphia, Pennsylvania 19104, USA (“Spark”), and Genable Technologies Limited, a limited liability company with a principal address at c/o Delta Partners, Media House, South County Business Park, Leopardstown,
Dublin 18, Ireland (“Genable”). Spark and Genable may each be referred to herein as a “Party” and together as the “Parties”. 

WHEREAS, Genable is a company engaged in the discovery and development of biological products, including the Product (as defined
below); 
 WHEREAS, Spark has unique and valuable experience, skill and ability in, among other things, the research,
development and manufacture of AAV-based therapeutic products; and 
 WHEREAS, Genable desires, and Spark is willing to
provide to Genable, certain manufacturing services in accordance with the terms and conditions of this Agreement. 
 NOW,
THEREFORE, in consideration of the promises, rights and obligations set out in this Agreement, the sufficiency of which is hereby acknowledged and intending to be legally bound, the Parties agree as follows: 

 

	1	Definitions. 

 The following terms shall have the meanings ascribed to them below: 

 

	 	1.1	“AAV” shall mean adeno associated virus. 

  

	 	1.2	“Affiliate” shall mean, with respect to a Party, any Person that directly or indirectly controls, is controlled by, or is under common control with, such Party. For these purposes, “control”
and its correlates means: (i) the ownership, directly or indirectly, of at least fifty percent (50%) of the issued voting shares or interests in an entity; or (ii) the possession, directly or indirectly, of the legal power to direct
or cause the direction of the general management and policies of an entity, whether through the ownership of voting securities, by contract or otherwise. Notwithstanding the foregoing, CHOP shall be deemed not to be an Affiliate of Spark.

  

	 	1.3	“Agreement” shall have the meaning set forth in the Preamble. 

  

	 	1.4	“Batch” shall mean a specific quantity of a Product that is intended to be of uniform character and quality and is produced during the same cycle of manufacture and in accordance with the applicable
manufacturing process. 

  

	 	1.5	 “cGMP” shall mean current good manufacturing practices pursuant to (a) the U.S. Federal Food, Drug, and Cosmetic Act as amended
(21 USC 301 et seq.), (b) relevant U.S. regulations found in Title 21 of the U.S. Code of Federal Regulations 

  
 1 

	 	
(including but not limited to Parts 11, 210, 211, 600 and 610), (c) Commission Directive 2003/94/EC of 08 October 2003, (d) the EC Guide to Product Manufacturing Practice for
Medicinal Drug Products, including respective guidance documents and (e) any comparable laws, rules or regulations of any agreed upon foreign jurisdiction, as each may be amended from time to time. cGMP also includes adherence to any applicable
product license requirements, to the current requirements of the United States Pharmacopoeia/National Formulary, the current requirements of the European Pharmacopoeia and the relevant current International Conference on Harmonization (ICH) guidance
documents. 

  

	 	1.6	“CHOP” shall mean The Children’s Hospital of Philadelphia. 

  

	 	1.7	“Claim” shall have the meaning set forth in Section 12.1.1. 

  

	 	1.8	“Commercially Reasonable Efforts” shall mean the carrying out of applicable obligations under this Agreement in a commercially reasonable manner in good faith using all such efforts and resources
consistent with the practice of comparable contract manufacturers of a similar size and resources, both financial and otherwise, to Spark, that would be used by such companies were they developing a comparable biological product, and in any event
Spark shall be required to perform all services under this Agreement to a standard comparable to that used in respect of the development of its own products and/or internal projects; 

 

	 	1.9	“Confidential Information” shall have the meaning set forth in Section 14.1. 

  

	 	1.10	“Delivery Failure” shall have the meaning set forth in Section 9.1. 

  

	 	1.11	“Development Agreement” shall mean the Development Consultancy Agreement of even date herewith, by and between the Parties. 

 

	 	1.12	“DMF” shall mean Device or Drug Master File, as defined in the CFR Section 314.420 or 814 and/or its equivalent in the other countries in which Regulatory Approval for the Product has been secured.

  

	 	1.13	“EMA” shall mean the European Medicines Agency or any successor agency thereof having the authority to regulate the sale of medicinal or pharmaceutical products in the European Union through marketing
approval, not including any governmental authority with responsibility solely for pricing or reimbursement approvals. 

  

	 	1.14	“Effective Date” shall have the meaning set forth in the Preamble. 

  

	 	1.15	“FDA” shall mean the United States Food and Drug Administration or any successor entity thereto. 

  

	 	1.16	“Genable” shall have the meaning set forth in the Preamble. 

  
 2 

	 	1.17	“Genable Assays” mean the proprietary assays of Genable relating to GT038 as more specifically set out in Exhibit C. 

 

	 	1.18	“Genable Intellectual Property” means any and all intellectual property rights owned, licensed or controlled by Genable relating to GT038 (other than pursuant to a license or sublicense from Spark).

  

	 	1.19	“Genable Improvement” means improvements which predominately relate to the Genable Intellectual Property and which are developed (i) by Genable outside this Agreement, (ii) by Genable or Spark
pursuant to this Agreement, and/or (iii) jointly by any combination of Genable or Spark or a third party (under contract to either party) pursuant to this Agreement. 

 

	 	1.20	“Genable Indemnitees” shall have the meaning set forth in Section 12.1.2. 

  

	 	1.21	“GT038” means a gene therapeutic comprising an AAV vector containing DNA encoding an RNAi targeting rhodopsin in combination with an AAV vector containing DNA encoding a rhodopsin gene for the treatment
of rhodopsin-linked, autosomal dominant retinitis pigmentosa (RHO-adRP), which is in development by Genable as of the Effective Date, and as such gene therapeutic may be modified after the Effective Date. 

 

	 	1.22	“Indemnified Party” shall have the meaning set forth in Section 12.2. 

  

	 	1.23	“Indemnifying Party” shall have the meaning set forth in Section 12.2. 

  

	 	1.24	“Intellectual Property” shall mean all (a) patents, patent applications, patent disclosures and all related continuation, continuation-in-part, divisional, reissue, reexamination, utility model,
certificate of invention and design patents, patent applications, registrations and applications for registrations; (b) trademarks, service marks, trade dress, Internet domain names, logos, trade names and corporate names and registrations and
applications for registration thereof; (c) copyrights and registrations and applications for registration thereof; (d) mask works and registrations and applications for registration thereof; (e) computer software, data and
documentation; (f) inventions, trade secrets and confidential business information, whether patentable or nonpatentable and whether or not reduced to practice, know-how, manufacturing and product processes and techniques, research and
development information, copyrightable works, financial, marketing and business data, pricing and cost information, business and marketing plans and customer and supplier lists and information; and (g) copies and tangible embodiments thereof.

  

	 	1.25	“Legal Requirements” shall mean (a) any present and future national, state, local or similar laws (whether under statute, rule, regulation or otherwise), (b) requirements under permits,
orders, decrees, judgments or directives of any U.S. governmental entity and any governmental entity in the jurisdiction where the Manufacturing Services are performed, and (c) requirements of applicable Regulatory Authorities (including cGMP
and GLP) and Regulatory Approvals. 

  
 3 

	 	1.26	“License Agreement” shall mean the License Agreement of even date herewith, by and between the Parties. 

  

	 	1.27	“Manufacturing Price” shall mean, with respect to a Product, the applicable price (depending on type of production) calculated pursuant to Exhibit A. 

 

	 	1.28	“Manufacturing Services” shall have the meaning set forth in Section 3.1. 

  

	 	1.29	“Manufacturing Standard” shall have the meaning set forth in Section 7.7. 

  

	 	1.30	“Non-Conforming Product” shall mean any Product that at the time delivered pursuant to Section 9.1, does not meet the applicable Manufacturing Standard. 

 

	 	1.31	“Party” and “Parties” shall have the meanings set forth in the Preamble. 

  

	 	1.32	“Person” shall mean any individual, partnership, joint venture, limited liability company, corporation, firm, trust, association, unincorporated organization, governmental authority or agency, or any
other entity not specifically listed herein. 

  

	 	1.33	“Product” shall mean a product incorporating GT038, as further described in the applicable Specifications. 

  

	 	1.34	“Records” shall have the meaning set forth in Section 4.1. 

  

	 	1.35	“Regulatory Approval” shall mean the final approval to market the Product in any country of the Territory. 

  

	 	1.36	“Regulatory Authority” shall mean with respect to the United States, the FDA, or, in the case of a country other than the United States, such other appropriate regulatory agency with similar
responsibilities for granting Regulatory Approval for the Product, including but not limited to, the EMA. 

  

	 	1.37	“Retention Period” shall have the meaning set forth in Section 4.1. 

  

	 	1.38	“Senior Officers” shall have the meaning set forth in Section 15.2. 

  

	 	1.39	“Spark” shall have the meaning set forth in the Preamble. 

  

	 	1.40	“Spark Assays” mean the proprietary assays of Spark as more specifically set out in Exhibit D. 

  

	 	1.41	“Spark Indemnitees” shall have the meaning set forth in Section 12.1.1. 

  

	 	1.42	“Spark Intellectual Property” means any and all intellectual property rights owned, licensed or controlled by Spark relating to the research, development and manufacture of AAV-based therapeutic
products. 

  

	 	1.43	 “Spark Improvement” means improvements which predominately relate to the Spark Intellectual Property and which are developed
(i) by Spark outside this 

  
 4 

	 	
Agreement, (ii) by Spark or Genable pursuant to this Agreement, and/or (iii) jointly by any combination of Spark or Genable or a third party (under contract to either party) pursuant to
this Agreement. 

  

	 	1.44	“Specifications” shall mean the manufacturing, quality and testing specifications for the Product as set out in each applicable Work Order. 

 

	 	1.45	“Term” shall have the meaning set forth in Section 5.1. 

  

	 	1.46	“Third Party” shall mean any Person other than the Parties and their respective Affiliates. 

  

	 	1.47	“U.S.” or “United States” shall mean the United States of America. 

  

	 	1.48	“Work Order” shall have the meaning set forth in Section 3.1. 

  

	2	Technology Transfer 

  

	 	2.1	As soon as possible following the execution of this Agreement, Genable shall provide to Spark, unless it has already done so prior to the execution of this Agreement, data regarding GT038, as Genable determines may
reasonably be required by Spark to successfully perform the Manufacturing Services. The foregoing data shall include, but shall not be limited to:- 

  

	 	(i)	appropriate in-vitro and in-vivo analytical methods and procedures; 

  

	 	(ii)	information as to handling and storage conditions; and 

  

	 	(iii)	the desired Specifications for the Product. 

  

	 	2.2	It is acknowledged by the Parties that the Genable Assays shall be required by Spark in order to perform the Manufacturing Services. Genable and Spark shall use Commercially Reasonable Efforts to complete the transfer
of the Genable Assays to Spark within [**] months of the execution of this Agreement. The Genable Assays shall remain the sole property of Genable at all times. Spark covenants and undertakes to Genable to maintain the Genable Assays in confidence
and not to use the Genable Assays for any other purpose other than the manufacture of the Product pursuant to this Agreement. 

  

	 	2.3	It is acknowledged by the Parties that the Spark Assays shall be required by Spark in order to perform the Manufacturing Services. Spark warrants to Genable that the Spark Assays are functioning and qualified/validated
as appropriate to the stage of development for the purpose of manufacturing biological for human use. The Spark Assays shall remain the sole property of Spark at all times. 

 

	 	2.4	Spark shall only be entitled to outsource assay testing to a Third Party listed in Exhibit E or to a Third Party approved by Genable, such approval not to be unreasonably withheld or delayed. 

  
 5 

	 	2.5	Each of the Parties shall bear all of their own expenses in relation to the performance of the services set out in this Section 2. 

 

	 	2.6	Spark shall remain the sole owner of the Spark Intellectual Property. Genable shall remain the sole owner of the Genable Intellectual Property. 

 

	 	2.7	Spark shall remain the sole owner of the Spark Improvements. Any Spark Improvements which are made jointly by at least one employee/consultant of Spark and at least one employee/consultant of Genable shall be assigned
to Spark by Genable at Spark’s request 

  

	 	2.8	Genable shall remain the sole owner of the Genable Improvements. Any Genable Improvements which are made jointly by at least one employee/consultant of Genable and at least one employee/consultant of Spark shall be
assigned to Genable by Spark at Genable’s request. 

  

	 	2.9	Spark grants to Genable an [**] to the Spark Improvements as are made jointly by at least one employee/consultant of Spark and at least one employee/consultant of Genable for use with GT038. 

 

	 	2.10	Genable grants to Spark an [**] to the Genable Improvements as are made jointly by at least one employee/consultant of Genable and at least one employee/consultant of Spark for the manufacture of AAV-based therapeutic
products; provided however, that any such use shall be subject to the provisions of Clause 3.4 of the Licence Agreement. 

  

	3	Manufacturing Services 

  

	 	3.1	Manufacturing Services; Work Orders. Genable may, from time to time during the term of this Agreement, request that Spark manufacture Batches of the Product (“Manufacturing Services”), and
following each such request the Parties shall enter into written work orders (each such work order, a “Work Order”) substantially in the form set forth in Exhibit B. 

 

	 	3.2	Spark shall use Commercially Reasonable Efforts to perform such Manufacturing Services in accordance with this Agreement, as more specifically agreed in the applicable Work Order. Each Work Order shall be deemed
incorporated into this Agreement. Notwithstanding the foregoing, if for any reason Product as delivered by Spark does not conform to the Specifications, such nonconformity shall be addressed in accordance with Section 9.1. 

 

	 	3.3	Each Work Order shall include (a) the Specifications applicable to the applicable Batch; (b) an allocation of responsibility for quality assurance for the Batch; (c) timelines related to the delivery of
the Batch; (d) a detailed cost and pricing schedule, including the timing for the invoicing of costs; (e) a purchase order authorizing the initiation of work thereunder and (f) payment of [**]% of the price for the Work Order.

  
 6 

	 	3.4	The Parties from time to time may agree in writing on variations to the Specifications, depending on whether the Product supplied hereunder is intended to be cGMP, cGMP-comparable or research grade and depending on
whether the Product supplied hereunder will be in bulk form or final finished form, and shall reference the Specifications applicable to each Work Order in the Work Order. 

 

	 	3.5	The Parties shall agree on each binding Work Order [**] months before the delivery date specified therein for the applicable Batch, provided that the Parties will agree to Work Orders for the first GLP Batch and for the
first GMP Batch less than [**] months before the delivery date specified therein. In the event of any conflict between the terms of a Work Order and this Agreement, with the exception of the Specifications, the terms of this Agreement shall control.
Without limiting the foregoing, Genable shall [**] basis, provide Spark with a non-binding, good faith [**] month forecast of Genable’s anticipated requirements for Product. Prior to the commencement of commercial scale manufacture and supply
of Product by Spark to Genable, the Parties shall review forecasting, ordering and capacity commitments with respect to such manufacture and supply. 

  

	 	3.6	Performance Standard; Compliance with Law. Spark shall perform the Manufacturing Services (a) in a professional, competent and timely manner in conformance with the applicable Work Order and (b) in
compliance with all applicable Legal Requirements, provided that, Spark’s failure to comply with the foregoing obligations of this Section 3.6(b) shall not constitute a breach of this Agreement unless and until Genable has notified Spark
in writing of the noncompliance and Spark has failed to correct the noncompliance within [**] days thereafter. 

  

	 	3.7	Equipment. As between the Parties, unless otherwise specified in an applicable Work Order, Spark shall be responsible for procuring all facilities, equipment and staff necessary to perform Manufacturing Services
under each Work Order. Spark shall use Commercially Reasonable Efforts to make available all staff, facilities, equipment and other resources as may be necessary to support the provision of the Manufacturing Services pursuant to this Agreement.

  

	 	3.8	Licenses and Permits. Spark shall have and maintain any and all licenses, permits and other authorizations, which are required for its performance of this Agreement, provided that Genable shall reimburse Spark
for all reasonable costs and expenses of undergoing pre-approval inspections and other regulatory inspections solely related to the Product. Subject to the foregoing, Spark shall be solely responsible for all regulatory inspections relating to the
approval of the Manufacturing Facility. 

  

	 	3.9	 Spark shall be responsible for filing and maintaining a DMF for the Product with the FDA as its owner. Spark grants Genable the right to reference the
DMF in its regulatory filings for Products. Spark shall cooperate with Genable for purposes of creating a Common Technical Document and Genable will be permitted to reference and file EMA summary modules 2.3 and 3.0 of the Common Technical Document
in such manner as may be necessary in ex-U.S. regulatory filings 

  
 7 

	 	
relating to the sale and marketing of Products. Genable’s use of EMA summary modules 2.3 and 3.0 of the Common Technical Document shall be limited to such uses with respect to the Product.
Genable shall solely bear all reasonable costs related to the development and maintenance of EMA summary modules 2.3 and 3.0 of the Common Technical Document. 

  

	 	3.10	Joint Manufacturing Committee. As soon as practicable after the Effective Date, the Parties will form a Joint Manufacturing Committee (the “Joint Manufacturing Committee”), a subcommittee of the
Steering Group. The Joint Manufacturing Committee will meet regularly during the Term, as mutually agreed by the Parties. The meetings shall be by telephone conference or videoconference, or in person at mutually agreed locations. Each Party shall
be responsible for its own costs in attending meetings. The Joint Manufacturing Committee will not have the power to amend or waive compliance with the terms of this Agreement or any Work Order. The Joint Manufacturing Committee shall have the
responsibilities of monitoring the progress and results of the activities of the Parties pursuant to this Agreement and of facilitating coordination between the Parties with respect to such activities. 

 

	 	3.11	Process Modifications. Spark shall not be entitled to modify the process employed in the manufacture of the Product as set out in the DMF without first having consulted with Genable and then only with
Genable’s prior written agreement and also in compliance with all applicable regulatory requirements in the United States and EU with respect to such modification. 

 

	 	3.12	Subcontractors. Spark shall not sub-contract the performance of the Manufacturing Services to any Third Party other than CHOP without the priorwritten consent of Genable, provided that nothing in
this Agreement shall restrict Spark or CHOP from employing contractors to perform ancillary aspects of the Manufacturing Services under its supervision. Spark shall be responsible for any services it sub-contracts to a third party as if it had
performed those services itself. 

  

	 	3.13	Exclusivity. During the Term, except as otherwise set forth in Section 9.1, Genable shall purchase Product exclusively from Spark, and Spark shall supply Product exclusively to Genable. 

 

	4	Records and Facility; Audits 

  

	 	4.1	 Facility and Records. Spark shall maintain its manufacturing facilities used in manufacturing the Products in accordance with cGMP and all
other applicable Legal Requirements. Spark shall keep and maintain documents and records associated with the performance of Manufacturing Services as required by Legal Requirements. Spark will maintain all materials, data and documentation obtained
or generated by Spark in the course of performing the Manufacturing Services, including all reference standards, retained samples of Product and key intermediates, and computerized records and files (the “Records”) in a
secure area reasonably protected from fire, theft and destruction for the longer of (a) a period of 

  
 8 

	 	
[**] years following expiration or termination of this Agreement or (b) [**] years past the last expiration date of Product supplied under this Agreement, or, in each case, such longer
period as is required by applicable law (the “Retention Period”). At the end of the Retention Period, all Records will, at Genable’s option, either be (x) delivered to Genable or to its designee, at Genable’s
cost, in such form as is then currently in the possession of Spark or (y) disposed of, at the cost, direction and written request of Genable. In no event will Spark dispose of or destroy all copies of a particular Record without first giving
Genable at least [**] days’ prior written notice of its intent to do so and an opportunity to have the Records transferred to Genable. While in the possession and control of Spark, Records will be available during audits or at other mutually
agreed times for inspection, examination or review by Genable and its representatives as provided herein. Notwithstanding anything in this Section 4.1 to the contrary, Spark may retain copies of any Records as necessary to comply with Legal
Requirements, subject to the obligations of confidentiality of Spark under this Agreement and as consistent with Spark policies and practices. 

  

	 	4.2	Audit by Genable. Spark will permit Genable representatives (which may include representatives of Genable’s Affiliates and any of their respective consultants or sublicensees), upon reasonable advance notice
to Spark, to conduct, during normal business hours during the Term, audits and inspections of Spark’s records related to Manufacturing Services and Spark’s manufacturing facility. Genable shall be responsible for the costs incurred by
Genable in performing such audits. Genable shall conduct audits and inspections under the preceding sentence no more than [**] per facility (save where there has been a Delivery Failure, in which event Genable shall be entitled to conduct a further
audit during such calendar year) provided that (a) any vendor selection audit and preparatory audits conducted in preparation for a pre-approval inspection by a Regulatory Authority may be conducted in addition to the foregoing [**] audit; and
(b) Genable may conduct additional audits in the event any audit conducted by Genable or an audit by a Regulatory Authority reveals a compliance deficiency. All information disclosed or ascertained by Genable, its Affiliates, consultants or
sublicensees in connection with any audit or inspection will be deemed to constitute confidential information of Spark, subject to the terms of Article 14 and any Genable Affiliates, consultants or sublicensees acting hereunder shall be required to
sign confidentiality agreements consistent with the terms of Article 14 prior to any audit or inspection in which they take part. Notwithstanding the foregoing or anything to the contrary set forth in this Agreement, Spark shall have the right to
limit Genable’s access to confidential information relating to Spark’s manufacturing process to the extent not reasonably required to enable Genable to conduct such audits and inspections for quality assurance purposes. 

 

	 	4.3	 Regulatory Authority Inspections. Spark will be responsible for inspections of its facility by Regulatory Authorities, and will notify Genable
within [**] hours of receipt of notice from a Regulatory Authority of any such inspections that are specifically related to the Product or at least [**] days in advance of the scheduled inspection date for other inspections of its facility. Such
notifications may be given 

  
 9 

	 	
by telephone, e-mail or other reasonable communications method. With respect to inspections specifically related to the manufacture of Product or if the results of a non-specifically related
inspection could potentially impair the ability of Spark to perform the Manufacturing Services, Spark will (a) provide Genable with copies of all documents, reports or communications received from or given to any Regulatory Authority associated
therewith; and (b) permit Genable’s representatives to be on site in an adjacent area to answer questions or requests specific to Genable or the Product and, to the extent practicable, keep Genable apprised of the progress of such
inspections and consult with Genable regarding the same. 

  

	5	Term and Termination 

  

	 	5.1	Term. The term of this Agreement (“Term”) shall commence on the Effective Date and will expire ten (10) years after the first commercial sale of a Product. 

 

	 	5.2	Termination for Material Breach. This Agreement may be terminated by either Party if the other Party is in material breach of this Agreement and such material breach is not cured within [**] days after receipt of
written notice from the terminating Party with respect thereto. 

  

	 	5.3	Termination upon Termination of License Agreement. This Agreement shall terminate upon the expiration or termination of the License Agreement. 

 

	 	5.4	Effects of Termination; Survival. Upon termination or expiration of this Agreement, Genable shall pay Spark any undisputed monies due and owing Spark, up to the time of termination or expiration, including all
authorized expenses and non-cancelable expenses which have been incurred by Spark prior to the notice of termination in accordance with the relevant Work Order (which costs shall not in any event exceed the amounts agreed herein or in the Work
Order). Spark shall use its reasonable endeavors to cancel commitments prior to the termination. Termination of this Agreement for any reason is without prejudice to the Parties’ accrued rights and shall not be construed to release either Party
from any obligation incurred prior to the effective date of such termination. The following provisions shall survive the expiration or termination of this Agreement: Articles 4, 10, 12, 13, 14, 15 and 16. 

 

	6	Prices/Payment 

  

	 	6.1	Fees. The supply price for Product shall be the Manufacturing Price for such Product, as such supply price may be modified by the Work Order. 

 

	 	6.2	Additional Manufacturing Services. In the event that Spark is requested to perform any additional manufacturing services for Genable other than as provided for in the Manufacturing Price for the Product, the cost
of any such additional manufacturing services shall be agreed in advance in writing by the Parties and set forth in the Work Order. 

  
 10 

 Invoices. Spark shall invoice Genable for all amounts due under a Work Order in
accordance with the timing set forth in the Work Order. Invoices shall, except to the extent correctly disputed, be payable within [**] days after Genable’s receipt thereof. Genable shall be responsible for the payment of all taxes arising from
any Work Order or delivery or use of the Product (other than taxes on the income of Spark arising therefrom). For the avoidance of doubt, Genable shall pay to Spark within [**] days of Spark receiving from Genable a properly executed work start
order [**]% of the total cost of the Work Order. 
 The remaining [**]% payment shall be made within [**] days of Genable receiving
the finished goods. 
  

	 	6.3	 If applicable laws of Ireland require that withholding taxes be withheld with respect to any payments by Genable to Spark under this Agreement,
Genable will: (a) deduct those taxes from the remittable payment, (b) pay the taxes to the proper taxing authority, and (c) send evidence of the obligation together with proof of tax payment to Spark on a timely basis following that
tax payment. If Spark is a taxable entity in the United States and is therefore entitled to the benefits of the double taxation treaty between Ireland and the United States, and Spark provides Genable with a Form 6166 from the United States Internal
Revenue Service with respect to such taxable status, at or prior to the time of any payment potentially subject to the Irish withholding tax is made hereunder, then payments made by Genable to Spark hereunder shall be made without withholding tax;
provided that, if such double taxation treaty is modified after the Effective Date so that payments to Spark hereunder are subject to withholding taxes, Genable shall give notice to Spark of such change and shall pay to Spark such additional amount
as may be necessary so that Spark shall receive, after deduction of such withholding tax, the amount which Spark would have received in the absence of such withholding tax less [**] percent ([**]%) of the withholding tax amount (i.e., the Parties
[**] percent ([**]%) of the withholding tax amount). If Spark is not able to meet the above criteria for withholding tax treaty benefits (e.g., by ceasing to be, or by assigning its interest in this Agreement to an entity that is not, a taxable
entity in the United States entitled to the benefits of the double taxation treaty between Ireland and the United States), then Genable shall make payments less any required withholding tax, and such withholding taxes required under Irish law shall
be borne solely by Spark. If Genable or any successor or assign of Genable makes any payment to Spark hereunder in a manner that subjects such payment to a withholding tax obligation under the laws of any jurisdiction other than those of Ireland
(i.e., either by such entity being or becoming domiciled in any jurisdiction other than Ireland or by such entity making any payment to Spark from a jurisdiction outside of Ireland), then Genable shall give notice to Spark of such requirement and
shall pay to Spark such additional amount as may be necessary so that Spark shall receive, after deduction of such withholding tax, the amount which Spark would have received in the absence of such withholding tax. Each Party agrees to cooperate
with the other Party in claiming refunds or exemptions from such deductions or withholdings under any relevant agreement or treaty that is in 

  
 11 

	 	
effect (e.g., Genable shall not withhold Irish withholding tax without first confirming with Spark that Spark is not able to provide the documentation of its taxable status as described above).
The Parties shall discuss and cooperate regarding applicable mechanisms for minimizing such taxes to the extent possible in compliance with applicable law. In addition, the Parties shall cooperate in accordance with applicable law to minimize
indirect taxes (such as value added tax, sales tax, consumption tax and other similar taxes) in connection with this Agreement. 

  

	7	Spark’s Representations and Warranties 

  

	 	7.1	General Representations and Warranties. Spark hereby represents and warrants to Genable that it has the power to enter into this Agreement, and its performance hereunder will not violate any Legal Requirements
and will not breach or in any way be inconsistent with the terms and conditions of any license, contract, understanding or agreement, whether express, implied, written or oral between Spark and any third party. 

 

	 	7.2	No Conflict. Spark hereby represents and warrants to Genable that it is not a party to any agreement that (a) would prevent Spark from performing its obligations under this Agreement; or (b) conflicts
with Spark’s performance of its obligations under this Agreement. 

  

	 	7.3	Personnel; No Debarment. Spark represents and warrants that all of the personnel that Spark uses in the performance of the Manufacturing Services shall be appropriately qualified and experienced for the tasks
that they are to perform. Spark warrants and covenants that all Spark employees and personnel that perform such Manufacturing Services are and will be subject to binding, written non-disclosure policies as are reasonably necessary for Spark to
comply with the confidentiality obligations hereunder and the provisions of Article 14. 

  

	 	7.4	Spark represents that it has never been and to the best of its knowledge, none of its employees or contractors assigned to perform the Manufacturing Services has ever been, (a) debarred or threatened to be debarred
under applicable law, or (b) indicted for a crime or otherwise engaged in conduct for which a person can be debarred under 21 U.S.C. § 335a, as amended. Spark shall promptly disclose in writing to Genable (i) if Spark is debarred, is
proposed to be debarred or if any action or investigation is pending relating to the debarment of Spark, or (ii) if an employee or agent of Spark assigned to perform Manufacturing Services is debarred, is proposed to be debarred, or if any
action or investigation is pending relating to the debarment of an employee or agent of Spark assigned to perform Manufacturing Services. 

  

	 	7.5	Product Warranties; Disclaimers. Genable acknowledges, without limiting Spark’s responsibility for delivering Products that conform to the Manufacturing Standard, that the Product is experimental in nature
and may have unknown characteristics, may carry infectious agents, or may be otherwise hazardous. 

  
 12 

	 	7.6	EXCEPT AS EXPRESSLY SET FORTH BELOW IN SECTION 7.7, THE PRODUCT IS PROVIDED “AS IS” AND SPARK (INCLUDING THE SPARK INDEMNITEES) DISCLAIMS ANY WARRANTY, EXPRESS OR IMPLIED, WITH RESPECT TO THE PRODUCT,
INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE PRODUCT WILL NOT INFRINGE OR VIOLATE ANY INTELLECTUAL PROPERTY RIGHT OF ANY THIRD PARTY.

  

	 	7.7	Spark represents and warrants to Genable that Product manufactured and supplied hereunder, including under any Work Order hereunder, (a) will conform to the applicable Specifications in each Work Order;
(b) will be manufactured and supplied in compliance with applicable Legal Requirements (including cGMP, to the extent applicable) and Regulatory Approvals to the extent required under the applicable Work Order and Specifications; and
(c) except as otherwise specifically set forth in writing in the applicable Work Order, will not be adulterated, contaminated or misbranded (“Manufacturing Standard”). 

 

	8	Genable’s Representations and Warranties; Obligations 

  

	 	8.1	General Representations and Warranties. Genable hereby represents and warrants to Spark that (a) it has the power to enter into this Agreement, and (b) its performance hereunder will not violate any
Legal Requirements. 

  

	 	8.2	No Conflict. Genable hereby represents and warrants to Spark that it is not a party to any agreement that (a) would prevent Genable from performing its obligations under this Agreement; or (b) conflicts
with Genable’s performance of its obligations under this Agreement. 

  

	 	8.3	Genable Supplied Materials. In case of material provided by Genable for use in the manufacturing of Products at Spark’s facilities, Genable is responsible for ensuring that such Genable supplied material is
provided in time for the work to commence or continue as planned, in compliance with the applicable Specifications, is delivered with all necessary documentation and that Spark may use such material in accordance with the applicable Work Order
without violating the Intellectual Property rights of any Third Party. Spark shall not use any Genable supplied materials for any purpose other than the performance of Manufacturing Services without the prior written consent of Genable. Upon
completion of the relevant Manufacturing Services, any remaining quantities of Genable supplied materials will be, at Genable’s option, either destroyed by Spark or returned to Genable. 

 

	 	8.4	Genable Obligations. Genable shall provide Spark with any documentation or knowledge in its possession and control pertaining to known risks associated with GT038. This includes material safety data sheets for
raw materials, intermediates and final product, chemical and operational hazard assessments and materials compatibilities. 

  
 13 

	9	Delivery Requirements; Transfer of ownership and risk 

 Spark shall use Commercially
Reasonable Efforts to deliver Products in accordance with the terms of the relevant Work Order, including delivery dates and shipping instructions set forth therein. Spark shall promptly (within [**] days) notify Genable if it becomes aware or
believes that it will not be able to fully satisfy a particular delivery on time (in each case, a “Delivery Failure”), which notice shall include an explanation in reasonable detail of the reasons for such Delivery Failure, a
detailed description of the action to be taken to remedy such failure, including an estimate of the time required to fulfill the obligations that were the subject of the Delivery Failure. The Parties shall promptly discuss the Delivery Failure. 

If (i) a Delivery Failure persists for more than [**] consecutive days or (ii) there are delays in filling each of [**] successive
orders which delays cumulatively exceed [**] days when each delay is measured beginning on the due date for delivery or (iii) there is a shortfall in [**] successive orders delivered by Spark which on a cumulative basis, exceeds [**] percent
([**]%) of the total amount of said [**] orders, then, at Genable’s request and at Spark’s sole cost and expense, and subject to the execution of a contract between Genable and the applicable Third Party protecting Spark’s
intellectual property and trade secret rights therein (in the same manner to the extent set forth herein including restricting their use to the supply of Product to Genable), Spark shall provide all assistance and cooperation as are reasonably
required by Genable to transfer Spark’s manufacturing process for the Product to Third Party contract manufacturer selected by Genable and reasonably acceptable to Spark, provided however that Spark shall only be entitled to object to such
Third Party where Spark can show documentary evidence that such Third Party will not maintain the confidentiality of Spark’s intellectual property. To this end, Spark shall impart to the Third Party the documentation constituting the required
material support, more particularly practical performance advice, shop practice, specifications as to materials to be used and control methods. For this purpose, Spark shall receive the Third Party’s scientific and manufacturing staff in its
premises for periods the term of which shall be decided in good faith by common consent. 
  

	 	9.1	Applicable Incoterms. Unless otherwise agreed, all Products are supplied Ex Works Spark’s manufacturing facility in Philadelphia as defined in Incoterms 2010. 

 

	 	9.2	Certificates. An appropriate certificate of analysis shall precede the shipment of Products to Genable. Genable shall be entitled to rely upon such certificate of analysis without the requirement to perform
additional testing. 

  

	10	Acceptance; Non-Conforming Products 

  

	 	10.1	 Testing by Spark. Unless otherwise specified in the applicable Work Order, after manufacture of Products, Spark shall perform quality testing
in order to assure that the Products comply with the applicable Specifications, shall retain samples and records of the tests made on each such Batch and shall be responsible for release thereof, provided that, as to releases of Product for the EU,
Genable may be 

  
 14 

	 	
required perform a second release thereof. Unless otherwise specified in writing in the applicable Work Order, no Product shall be delivered until it has been tested. Spark shall maintain records
with respect to the quality testing and shall deliver a certificate of analysis to Genable by facsimile or email and overnight courier prior to delivery of the Products. Spark’s records with respect to such testing shall also be available for
inspection by Genable during normal business hours, upon prior written request, in accordance with Section 5.2. Spark shall promptly notify Genable of any Non-Conforming Products of which it becomes aware, which have been delivered to Genable.

  

	 	10.2	Identification of Non-Conforming Product. At Genable’s election, Products may be subjected to testing by Genable in order to verify conformance to the applicable Specifications. Genable shall notify Spark of
any Non-Conforming Product within the earlier of [**] days after Genable becomes aware of the non-conformity or [**] days after delivery of the Product. Spark shall have the right to examine and test any Products in Genable’s possession that
Genable claims is Non-Conforming Product. The Parties shall cooperate to determine the point at which the non-conformance arose. Spark shall not be responsible for any naturally occurring degradation of Products after delivery thereof by Spark,
provided that such degradation does not result from Products failing to conform to the applicable Specifications when delivered, or any damage to the Products making them Non-Conforming Products caused by Genable’s carrier or Genable. If the
Parties fail to agree as to whether Product is Non-Conforming Product, then the Parties will promptly select a mutually acceptable, independent laboratory to evaluate if the Product is Non-Conforming Product. Such evaluation will be binding on the
Parties, and if such evaluation certifies that the Product is Non-Conforming Product, Spark shall be liable for the costs of such evaluation. If such evaluation reveals that the Product in question complies with the Specifications, then Genable
shall be liable for the costs of such evaluation. 

  

	 	10.3	Remedy. With respect to any Non-Conforming Product, at Genable’s option, Spark shall (a) without additional charge to Genable, replace such Non-Conforming Product with corresponding Product meeting the
relevant Specifications or (b) refund any amounts paid by Genable with respect to such Non-Conforming Product. Spark shall also be responsible for delivery costs and expenses which may be incurred directly or indirectly by Genable, its
Affiliates, licensees and/or sub-licensees with respect to the return to Spark of Non-Conforming Product or the shipment to Genable of replacement Product. 

  

	 	10.4	Complaints. Spark shall timely cooperate in investigating and completing investigations of complaints and deviations, including providing information applicable to each. 

 

	11	Force Majeure 

 Neither Party shall be held liable for any delay or failure in the
performance of any part of this Agreement or any breach of contract resulting from force majeure events, including 

  
 15 

 
but not limited to fire, flood, explosion, war, strike, embargo, act of God or similar causes. If either Party is affected by an event of force majeure, it will forthwith notify the other Party
of the nature and extent of such force majeure event and the Parties will enter into bona fide discussions with a view to alleviating its effects and to agreeing to such alternative arrangements as may be fair, reasonable and practicable. The Party
affected by a force majeure is under obligation to give full particulars thereof and to use its best efforts to minimize the effect of occurrence and to take the necessary remedial measures. If as a result of a force majeure event, Spark’s
performance, in whole or material part, of the Manufacturing Services is suspended for more than [**] days, Genable shall have the right to terminate the Agreement and/or any affected Work Order hereunder by giving written notice to that effect to
Spark. 
  

	12	Indemnification; Insurance 

  

	 	12.1	Indemnification. 

  

	 	12.1.1	Genable shall indemnify, defend, and hold harmless Spark and its officers, directors, employees, members of its medical staff and agents (collectively “Spark Indemnitees”) from any claim, loss,
judgment, liability, damage, settlement, fine or expense of any kind whatsoever (including reasonable attorneys’ fees, interest, penalties and costs) (a “Claim”) that may arise from or be asserted by any Third Party in
connection with any of the following: (A) Genable’s conduct of research in any form utilizing the Product; (B) Genable’s distribution or other commercialization of the Product; (C) Genable’s use, handling, study,
storage, return, or disposal of the Product; (D) Genable’s breach of this Agreement; or (E) Genable’s failure to conform to law or regulation applicable to (1) this Agreement or the subject matter hereof, (2) to the
Product, or (3) to any research or activity conducted by Genable involving the Product provided, however, that to the extent that any such Claim results solely from the negligence or misconduct of, or breach of this Agreement by, a Spark
Indemnitee, or from any matter for which Spark is obligated to indemnify Genable pursuant to Section 12.1.2, Genable shall have no such indemnity obligation to such extent with respect to any such Spark Indemnitee. 

 

	 	12.1.2	Spark shall indemnify, defend, and hold harmless Genable and its officers, directors, employees, members of its medical staff and agents (collectively “Genable Indemnitees”) from any Claim that
may arise from or be asserted by any Third Party in connection with any of the following: (A) for death or personal injury arising from any failure by Spark to deliver Product conforming to the Manufacturing Standard, (B) Spark’s
breach of this Agreement; or (C) Spark’s failure to conform to law or regulation applicable to the Manufacturing Services, provided, however, that to the extent that any such Claim results from the negligence or misconduct of, or breach of
this Agreement by, a Genable Indemnitee, or from any matter for which Genable is obligated to indemnify Spark pursuant to Section 12.1.1, Spark shall have no such indemnity obligation to such extent with respect to any such Genable Indemnitee.

  
 16 

	 	12.1.3	Procedure. To the extent reasonably feasible, the Party entitled to indemnification under Section 12.1.1 or 12.1.2 above (the “Indemnified Party”) shall notify the other Party (the
“Indemnifying Party”) in writing of any Claim that, in Indemnified Party’s reasonable judgment, is likely to lead to a claim for indemnification. The Indemnifying Party shall promptly assume the entire defense of such
Claim following the Indemnified Party’s written notice and reimburse the Indemnified Party for all expenses incurred prior to the Indemnifying Party’s assuming the defense of such Claim. The Indemnifying Party may settle a claim on terms
which provide only for monetary relief, include a full release of the Indemnified Party and do not include any admission of liability, wrongdoing, infringement or invalidity or unenforceability of patent rights owned or controlled by the Indemnified
Party. Save as aforesaid, neither the Indemnifying Party nor the Indemnified Party shall acknowledge the validity of, compromise or otherwise settle any claim without the prior written consent of the other Party, which shall not be unreasonably
withheld or delayed. The Indemnified Party shall use cooperate with the Indemnifying Party in the defense of the Claim at the Indemnifying Party’s sole expense. The Indemnified Party may hire its own counsel, at its own expense, to monitor, but
not control, the defense of any Claim. The Indemnified Party and the Indemnifying Party may execute such mutually acceptable confidentiality and joint defense agreements to protect privileged materials as shall be usual and customary in such
proceedings and as shall be reasonably requested in writing by either the Indemnified Party or the Indemnifying Party. 

  

	 	12.1.4	 Insurance. Each Party shall obtain and maintain throughout the term of this Agreement and for a period of [**] years after the termination of
this Agreement insurance policies of such types (including professional liability, broad form comprehensive general liability and product liability) and in such amounts (but in no case less than $[**] annual limits per policy or $[**] annual
aggregate) as shall be reasonably required to protect itself and the other Party from potential liabilities, risks and claims arising under this Agreement and/or from the performance of such Party’s acts or omissions arising in connection with
or under this Agreement. The other Party shall be named prior to initiation of Manufacturing Services as an additional insured on all such policies of insurance throughout the term of this Agreement and for [**] years thereafter. Prior to initiation
of the Manufacturing Services, each Party shall provide the other Party with certificates from each of the insured Party’s insurers issuing insurance required under this Agreement evidencing the status of the other Party as an additional
insured on each such policy. All policies of insurance required hereunder shall be placed with insurers with a current A.M. Best rating of A-VII or better except as otherwise approved in writing by the other Party.

  
 17 

	 	
Each policy of insurance obtained by a Party as required hereunder shall be endorsed to state that coverage shall not be suspended, voided, cancelled, reduced in coverage amounts or in limits or
otherwise materially modified unless [**] days advance written notice of such proposed change has been given to the other Party. 

  

	13	Limitation of Liability 

  

	 	13.1	Except with respect to the indemnification obligations of Article 12, neither Party’s overall liability with respect to any Work Order shall exceed three times the total amounts paid or payable to Spark under such
Work Order. 

  

	 	13.2	In no event shall either Party be liable to the other Party, and each Party shall procure that none of its Affiliates shall make any claim against the other Party (or its Affiliates), for lost profits, loss of business,
loss of contracts, diminished goodwill, diminished reputation, or consequential, indirect, incidental, punitive or special damages arising under or in connection with this Agreement. 

 

	14	Confidentiality 

  

	 	14.1	Each Party undertakes with the other that it shall keep, and that it shall procure that its respective directors and employees keep secret and confidential all know-how, technical, business and other information that
has the quality of confidentiality and that is communicated to it by the other Party under or in respect of this Agreement or acquired from any other Party as a result of this Agreement (“Confidential Information”) and shall not
disclose the same or any part of the same to any person whatsoever SAVE THAT either Party may disclose Confidential Information to its Affiliates and any of its directors, employees, consultants or subcontractors who are directly or indirectly
legitimately involved with the Manufacturing Services and who require the said Confidential Information for the purposes of the said involvement. 

  

	 	14.2	The non-disclosure provision of Section 14.1 shall not apply to: 

  

	 	(a)	Confidential Information in the public domain otherwise than by breach of this Agreement; 

  

	 	(b)	Confidential Information in the lawful possession of a Party prior to disclosure by any other Party as evidenced by written records; 

 

	 	(c)	Confidential Information that was created independent of disclosure as evidenced by written records; or 

  

	 	(d)	Confidential Information obtained from a Third Party who is free to divulge the same. 

  

	 	14.3	The obligations of each Party under this Article 14 shall continue in force notwithstanding the termination of this Agreement. 

  
 18 

	 	14.4	Any Confidential Information disclosed by the disclosing Party shall be used by the receiving Party exclusively for the purposes of fulfilling the receiving Party’s rights and obligations under this Agreement and
for no other purpose. 

  

	 	14.5	A Party will be entitled to make a disclosure or public statement concerning the existence, subject matter or any term of this Agreement, or to disclose Confidential Information that the such Party is required to
disclose, pursuant to: 

  

	 	(a)	a valid order of a court or governmental authority; or 

  

	 	(b)	any other requirement of law or any securities or stock exchange; provided that, if such Party becomes legally required to make such announcement, public statement or disclosure hereunder, such Party shall (to
the extent possible) give the other Party prompt notice of such fact to enable the other Party to seek a protective order or other appropriate remedy concerning any such announcement, public statement or disclosure, including confidential treatment
and/or appropriate redactions. 

  

	 	14.6	The Party required to make a disclosure as described in Section 14.5 shall fully co-operate with the other Party in connection with that other Party’s efforts to obtain any such order or other remedy. If any
such order or other remedy does not fully preclude announcement, public statement or disclosure, the Party required to make the disclosure shall make such announcement, public statement or disclosure only to the extent that the same is legally
required. 

  

	15	Disputes 

  

	 	15.1	If a dispute arises which cannot be resolved in the normal course of events, any Party to the dispute may give notice in writing to the others specifying the subject matter of the dispute and its proposal for its
resolution. The Parties must procure that the dispute is considered by their respective authorized representatives and that such authorized representatives use all reasonable endeavors, in good faith, to resolve the dispute within 14 days of the
date of the notice specifying the dispute. If the authorized representatives reach agreement on the matter in dispute in the period specified in this Section 15.1, the Parties shall procure that their respective representatives sign a joint
memorandum to that effect recording the resolution and procure that such agreement is fully and promptly carried into effect. 

  

	 	15.2	If the authorized representatives fail to reach agreement, any Party may refer the matter to the Chief Executive Officers of the Parties (together, the “Senior Officers”). The Parties shall
respectively procure that the Senior Officers attempt in good faith to resolve the dispute. If the Senior Officers reach agreement on the matter in dispute within [**] days of the dispute being referred to them (or such other period as the Parties
may mutually agree in writing) the Parties shall procure that their respective Senior Officers shall sign a joint memorandum to that effect recording the resolution and procure that such agreement is promptly and fully carried into effect.

  
 19 

	 	15.3	The dispute resolution procedure shall have been exhausted if the matter in dispute: 

  

	 	(i)	has not been resolved in accordance with Section 15.1 within the relevant period and is not referred to the Senior Officers within the relevant period; or 

 

	 	(ii)	where it is so referred, has not been resolved in accordance with Section 15.2 within the relevant period. 

  

	 	15.4	For the avoidance of doubt, the fact that the dispute resolution procedure has been exhausted without resolution shall not prevent the Parties from agreeing that the dispute be referred to an independent alternative
form of dispute resolution and/or to arbitration. 

  

	 	15.5	The foregoing provisions shall not prevent either Party from commencing legal proceedings or applying to the court for injunctive or other interim relief at any time. 

 

	 	15.6	Any controversy or claim related to or arising out of this Agreement (other than a patent dispute) shall be settled by arbitration conducted on a confidential basis under the Commercial Arbitration Rules of the
International Centre for Dispute Resolution (“ICDR”) in effect at the time of the arbitration (“Rules”). Any arbitration shall be held in Manhattan, New York before one disinterested arbitrator selected by mutual agreement of the
Parties; provided, however, that if the Parties are unable to agree on the arbitrator within [**] days, the arbitrator shall be appointed in accordance with the Rules. Any Party desiring arbitration shall serve on the other Party pursuant to
Section 16.6 and the regional case management center of the ICDR administering cases for such location in accordance with the aforesaid Rules, its notice of intent to arbitrate (“Arbitration Notice”). All arbitrations shall be
administered by the ICDR. 

  

	 	15.7	The arbitrator shall have no authority to award damages expressly precluded under this Agreement. The award of the arbitrator shall be final and binding upon the Parties and judgment upon such award may be entered and
enforced in any court of competent jurisdiction. Unless the arbitrator for good cause determines otherwise, the costs and expenses of the arbitrator shall be shared equally by the Parties and each Party will bear its own attorneys’ fees and
other costs associated with the arbitration proceeding. If court proceedings to stay litigation or compel arbitration are necessary, the Party that unsuccessfully opposes such proceedings will pay all associated costs, expenses and attorneys’
fees that are reasonably incurred by the other Party. The Parties intend that each award rendered by an arbitrator hereunder shall comply with the United Nations Convention on the Recognition and Enforcement of Arbitral Awards and shall be
enforceable in accordance therewith. 

  

	16	General Provisions 

  

	 	16.1	 Neither Party may waive or release any of its rights or interests in this Agreement except in writing. The failure of either Party to assert a right
hereunder or to insist 

  
 20 

	 	
upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right by such Party or excuse a similar subsequent failure to perform any such term or condition
by Genable. 

  

	 	16.2	This Agreement, together with the License Agreement and Development Consultancy Agreement of even date herewith between the Parties, constitutes the entire agreement between the Parties relating to the subject matter
hereof and thereof, and all prior negotiations, representations, agreements, and understandings are merged into, extinguished by, and completely expressed by such agreements. 

 

	 	16.3	The provisions of this Agreement are severable, and in the event that any provision of this Agreement shall be determined to be invalid or unenforceable under any controlling body of law such determination shall not in
any way affect the validity or enforceability of the remaining provisions of this Agreement. 

  

	 	16.4	If either Party desires a modification to this Agreement, the Parties shall, upon reasonable notice of the proposed modification by the Party desiring the change, confer in good faith to determine the desirability of
such modification. No modification will be effective until a written amendment is signed by the signatories to this Agreement or their designees. 

  

	 	16.5	The construction, validity, performance, and effect of this Agreement shall be governed by the Laws of the State of New York and, subject to Article 15, any and all actions or proceedings relating to this Agreement
shall be brought and pursued exclusively in the federal or state courts sitting in United States District Court for the Southern District of the State of New York. 

 

	 	16.6	Any notice required to be given under this Agreement shall be in writing and shall be delivered personally, or sent by pre-paid post or recorded delivery or by commercial courier, to each Party required to receive the
notice at its address as set out below: 

 Spark: 

Spark Therapeutics, LLC 
 3501
Civic Center Blvd., 5th Floor 
 Philadelphia, PA 19104 

USA 
 Attention: Jeffrey Marrazzo,
CEO 
 Genable: 
 Genable
Technologies Limited 
 c/o Delta Partners 

Media House, South County Business Park 

Leopardstown, Dublin 18 
 Ireland

 Attention: Jason Loveridge, CEO 

or as otherwise specified by the relevant Party by notice in writing to each other Party. 

  
 21 

 Any notice shall be deemed to have been duly received: 

 

	 	(i)	if delivered personally, when left at the address and for the contact referred to in this Section 16.6, or 

  

	 	(ii)	if delivered by commercial courier, on the date and at the time that the courier’s delivery receipt is signed. 

A notice required to be given under this Agreement shall not be validly given if sent by e-mail. The provisions of this Section 16.6
shall not apply to the service of any proceedings or other documents in any legal action. 
  

	 	16.7	This Agreement, or any obligations of a party under this Agreement, may not be assigned except as expressly provided in this Agreement. This Agreement may be assigned by either Party as part of a sale or transfer of
substantially the entire business of the assigning Party relating to operations which concern this Agreement, provided that the assigning Party notifies the other Party in writing within [**] days of any assignment of this Agreement by the assigning
Party. 

  

	 	16.8	Genable acknowledges that it is subject to and agrees to abide by the United States laws and regulations (including the Export Administration Act of 1979 and Arms Export Control Act) controlling the export of technical
data, computer software, laboratory prototypes, biological material, and other commodities. The transfer of such items may require a license from the relevant Agency of the U.S. Government or written assurances by Genable that it shall not export
such items to certain foreign countries without prior approval of such agency. Spark neither represents that a license is not required or that, if required, it shall be issued. 

 

	 	16.9	Neither Party shall issue any press releases or public disclosure relating to this Agreement without the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed. Neither
Party shall use the name or logo of the other Party, and Genable shall not use the name of past or present Spark employees, in any advertising, promotional or sales activities without prior written consent obtained from the other Party in each
separate case, except as otherwise provided in this Agreement. 

 In WITNESS OF THE FOREGOING, the Parties have caused their authorized
representatives to sign this Agreement: 
  

									
	GENABLE TECHNOLOGIES LIMITED	 		 	SPARK THERAPEUTICS, LLC
					
	BY:	 	 /s/ Jason Loveridge
	 		 	BY:	 	 /s/ Jeffrey D. Marrazzo

					
	NAME:	 	Jason Loveridge	 		 	NAME:	 	Jeffrey D. Marrazzo
					
	TITLE:	 	CEO	 		 	TITLE:	 	President & CEO

  
 22 

 EXHIBIT A 

GMP, GLP, and Research Viral Vector Price Structure 
  

			
	GLP:	  	$[**]
		
	GMP	  	$[**]

 [**]% payable within [**] days of placing of a binding work start order 

[**]% payable within [**] days of receipt of Finished Goods 

  
 23 

 EXHIBIT B 

WORK ORDER 001 
 This Work Order 001 (the
“Work Order”) is made this 18th day of March, 2014 (the “Effective Date”) by and between Spark Therapeutics, LLC, a Delaware limited liability company with a principal address
at 3501 Civic Center Boulevard, Philadelphia, Pennsylvania 19104, USA (“Spark”), and Genable Technologies Limited, an Irish Limited Company with a principal address at c/o Delta Partners, Media House, South County Business Park,
Leopardstown, Dublin 18, Ireland (“Genable”). Spark and Genable may each be referred to herein as a “Party” and together as the “Parties”. 

This Work Order is subject to the provisions of the Manufacturing Agreement between the Parties dated
18th March 2014. 
  

	A.	SCOPE OF WORK 

 The Work shall consist of the following: 

[**] 
  

	1.	GLP Work Order 

 [**] 

 

	2.	Release Testing of AAV2/5-xxxxxx 

 The Final Product AAV2/5-xxxxxx shall be subjected to
Release Testing as defined below, consistent with Spark’s Policy for Specifications for new products: 
  

					
	 TEST
	  	 STUDY

NUMBER
	  	 SPECIFICATION

		  	Final Product	  	
	Appearance (by visual inspection)	  	[**]	  	[**]
	pH (potentiometry)	  	[**]	  	[**]
	Osmolality (osmometry)	  	[**]	  	[**]
			
	Potency: Vector genome titer by Q-PCR GT038-S	  	[**]	  	[**]
	Potency: Vector genome titer by Q-PCR GT038-R	  	[**]	  	[**]
	Purity: SDS-PAGE/ Silver Staining	  	[**]	  	[**]
			
	Purity: OD260/OD280	  	[**]	  	[**]
			
	Purity: residual host cell DNA by Q-PCR	  	[**]	  	[**]
	Purity: Residual plasmid DNA by Q-PCR	  	[**]	  	[**]

  
 24 

					
	Purity: Residual BSA by ELISA	  	[**]	  	[**]
			
	Purity: Residual HEK293 proteins by ELISA	  	[**]	  	[**]
	Purity: Residual benzonase by ELISA	  	[**]	  	[**]
	Purity: Residual cesium by Mass Spec	  	[**]	  	[**]
	Safety: Bacterial endotoxin	  	[**]	  	[**]
			
	Safety: Sterility	  	[**]	  	[**]

  

	3.	Schedule for Work Order 

 Spark shall commence the Work order no later than [**] and
shall deliver the Finished Goods to Genable on or before the [**]. Finished Goods shall consist of: 
 [**] 

These total product amounts will be required for the Toxicology & Biodistribution Study, as Retained Samples, for Release Testing,
Stability Assessments, Assay Development and Qualification of the Assays and as Reference Standards. 
  

	4.	Stability testing 

 Stability testing of the Final Product AAV2/5-xxxxxx as defined in
the Schedule below shall be performed by Spark at its facilities and the results communicated to Genable in a detailed Report. 
  

																			
	Assay	  	SOP	  	Volume	  	Time Points (months)
		  		  	0**	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
										
	 Appearance Evaluation by Visual Inspection
	  	QC047	  	NA	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 Safety: Bioburden
	  	TBD	  	one
Container
(600uL)	  		  		  		  		  		  		  	[**]
	 Potency: Vector genome titer by Q-PCR
	  	QC011	  	100uL	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 Purity: SDS-PAGE/Silver Staining
	  	QC026	  	50uL	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 PH
	  	TBD	  	500uL	  		  	[**]	  		  	[**]	  		  	[**]	  	[**]
	 Light Scattering
	  	TBD	  	TBD	  		  	[**]	  		  	[**]	  		  	[**]	  	[**]
	 Potency: In-vitro activity*
	  	TBD	  	TBD	  		  	[**]	  		  	[**]	  		  	[**]	  	[**]
	 *  lf available
	  		  		  	[**]
	 Number of vials needed
	  	[**]	  		  	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 Number of reserve vials for re-test
	  	[**]	  		  		  		  		  		  		  		  	
	 Total number of vials for stability
	  	[**]	  		  		  		  		  		  		  		  	

  
 25 

	5.	Provided by Genable 

 Genable shall provide: 

[**] 
 All other materials
necessary to complete the Work Order shall be provided by Spark. 
  

	6.	Delivery of Finished Goods 

 Spark shall deliver to Genable or its nominee the Finished
Goods. 
  

	B.	PRICE & PAYMENT SCHEDULE FOR THE WORK 

 The Total Cost of the Work shall be
$[**]. 
 Genable shall pay to Spark within [**] days of Spark receiving from Genable a properly executed work start order [**]% of the total
cost of the Work Order. 
 The remaining [**]% payment shall be made within [**] days of Genable receiving the Finished Goods. 

AGREEED BY THE PARTIES 
  

									
	ON BEHALF OF SPARK THERAPEUTICS	 		 	ON BEHALF OF GENABLE TECHNOLOGIES
			
	 /s/ Jeffrey D. Marrazzo
	 		 	 /s/ Jason Loveridge

	NAME:	 	Jeffrey D. Marrazzo	 		 	NAME:	 	Jason Loveridge

  
 26 

 EXHIBIT C 

Genable Assays 
 In vitro assay for
suppression 

  
 27 

 EXHIBIT D 

Spark Assays 
  

					
	 TEST
	  	 STUDY NUMBER
	  	 SPECIFICATION

	 Safety: Viral Contaminants
 In Vitro, including
porcine circovirus
	  	BioReliance	  	[**]
	Safety: Agar Cultivable and Non-cultivable Mycoplasmas 1993 PTC	  	BioReliance	  	[**]
	 Appearance
 (by visual inspection)
	  	CCMT QC047	  	[**]
	pH (potentiometry)	  	CCMT QC028	  	[**]
	Osmolality (osmometry)	  	CCMT QC027	  	[**]
	Potency: Vector genome titer by Q-PCR	  	 CCMT QC011

QPR-07-022
	  	[**]
			
	Purity: SDS-PAGE/ Silver Staining	  	CCMT QC026	  	[**]
	Purity: OD260/OD280	  	CCMT QC121	  	[**]
	Purity: residual host cell DNA by Q-PCR	  	CCMT QC022	  	[**]
	Purity: Residual plasmid DNA by Q-PCR	  	CCMT QC023	  	[**]
	Purity: Residual BSA by ELISA	  	CCMT QC122	  	[**]
	Purity: Residual HEK293 proteins by ELISA	  	CCMT QC123	  	[**]
	Purity: Residual benzonase by ELISA	  	CCMT QC024	  	[**]
	Purity: Residual cesium by Mass Spec	  	 Quantitative

Technologies
	  	[**]
	Safety: Bacterial endotoxin	  	BioReliance	  	[**]
	Safety: Bioburden by direct inoculation	  	CCMT QC034	  	[**]
	Safety: Replication competent AAV by ICA	  	CCMT QC045	  	[**]
	Appearance by Visual inspection	  	CCMT QC047	  	[**]
	pH (potentiometry)	  	CCMT QC028	  	[**]
	Osmolality (osmometry)	  	CCMT QC027	  	[**]
	Vector genome identity by PCR	  	CCMT QC102	  	[**]
	Potency: Vector genome titer by Q-PCR	  	CCMT QC011	  	[**]
			
	Purity: SDS-PAGE/ Silver Staining	  	CCMT QC026	  	[**]
	Safety: General Safety	  	BioReliance	  	[**]
	Safety: Sterility <USP>, 21CFR	  	BioReliance	  	[**]
	Safety: Bacterial Endotoxin	  	 BioReliance

AB44MP.360012.BSV
	  	[**]
	Bacteriostatic/ Fungistatic activity	  	 BioReliance

AB44MP.510021.BSV
	  	[**]

  
 28 

 EXHIBIT E 

Pre-Approved third parties 
  

			
	[**]	  	[**]
	[**]	  	[**]
	[**]	  	[**]
	[**]	  	[**]
	[**]	  	[**]
	[**]	  	[**]
	[**]	  	[**]
	[**]	  	[**]
	[**]	  	[**]
	[**]	  	[**]

  
 29

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]